

# BMJ Open

## Exploring the Effect of Space and Place on Response to Exercise Therapy for Knee and Hip; a protocol for a double-blind randomised controlled clinical trial. The CONEX trial

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2015-007701
Article Type:	Protocol
Date Submitted by the Author:	16-Jan-2015
Complete List of Authors:	Sandal, Louise; University of Southern Denmark, Institute of Sport Science and Clinical Biomechanics Thorlund, Jonas; University of Southern Denmark, Institute of Sports Science and Clinical Biomechanics Ulrich, Roger; Chalmers University of Technology, Dieppe, Paul; University of Exeter Medical School, Institute of Health Research Roos, Ewa; University of Southern Denmark, Institute of Sports Science and Clinical Biomechanics
<b>Primary Subject Heading</b>:	Sports and exercise medicine
Secondary Subject Heading:	Rehabilitation medicine, Patient-centred medicine, Rheumatology
Keywords:	SPORTS MEDICINE, Hip < ORTHOPAEDIC & TRAUMA SURGERY, Knee < ORTHOPAEDIC & TRAUMA SURGERY, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY

SCHOLARONE™  
Manuscripts

1 Exploring the Effect of Space and Place on Response to Exercise Therapy  
2 for Knee and Hip; a protocol for a double-blind randomised controlled  
3 clinical trial. The CONEX trial  
4

5 **Author information**

6 Louise Fleng Sandal, Department of Sports Science and Clinical Biomechanics, University of Southern  
7 Denmark, Odense, Denmark, [lsandal@health.sdu.dk](mailto:lsandal@health.sdu.dk).

8 Jonas Bloch Thorlund, Department of Sports Science and Clinical Biomechanics, University of Southern  
9 Denmark, Odense, Denmark, [jthorlund@health.sdu.dk](mailto:jthorlund@health.sdu.dk)

10 Roger S. Ulrich, Chalmers University of Technology, Gothenburg, Sweden, [roger.s.ulrich@gmail.com](mailto:roger.s.ulrich@gmail.com)

11 Paul A. Dieppe, University of Exeter, Medical School, Exeter, UK, [p.dieppe@exeter.ac.uk](mailto:p.dieppe@exeter.ac.uk)

12 Ewa M. Roos, Department of Sports Science and Clinical Biomechanics, University of Southern Denmark,  
13 Odense, Denmark, [eroos@health.sdu.dk](mailto:eroos@health.sdu.dk)

14  
15 **Corresponding author:**

16 Louise Fleng Sandal, Ph.D. Student

17 Research Unit for Musculoskeletal Function and Physiotherapy

18 Department for Sports Science and Clinical Biomechanics

19 University of Southern Denmark

20 Campusvej 55

21 5230 Odense M

22 Denmark

23 Phone: + 45 65 50 43 84

24 Email: [lsandal@health.sdu.dk](mailto:lsandal@health.sdu.dk)

25

- 1 **Keywords:** Joint pain, context effect, exercise, physical environment.
- 2 Word count: 38434

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 ABSTRACT

### 2 Introduction

3 '*Context effects*' are described as effects of a given treatment, not directly caused by the treatment  
4 itself, but rather caused by the context in which treatment is delivered. Exercise is a recommended  
5 core treatment in clinical guidelines for musculoskeletal disorders. Although overall moderately  
6 effective, variation is seen in size of response to exercise across RCT studies. Part of this variation  
7 may be related to the fact, that exercise interventions are performed in different physical  
8 environments, which may affect participants differently. The study aims to investigate the effect of  
9 exercising in a contextually enhanced physical environment for 8 weeks for people with knee or hip  
10 pain.

### 12 Methods and analysis

13 The study is a double-blind randomised controlled trial. Eligible participants are 35 years or older  
14 with persisting knee and/or hip pain for 3 months. Participants are randomised to one of three  
15 groups; 1) exercise in contextually enhanced environment 2) exercise in standard environment 3)  
16 waiting list. The contextually enhanced environment is located in a newly built facility, has large  
17 windows providing abundant daylight, overlooking a recreational park. The standard environment is  
18 in a basement, has artificial lighting and is marked of use, i.e. resembling many clinical  
19 environments. Primary outcome is participant's global perceived effect rated on a 7-point Likert  
20 scale after 8 weeks exercise. Patient-reported and objective secondary outcomes are included.

### 22 Ethics and dissemination

23 Context effects may potentially add to the effect of and compliance with exercise therapy and  
24 consequently benefit people with chronic diseases, where exercise is recommended as treatment.

1

2 **Trial registration:** NCT02043613

3

#### 4 **Strengths and limitations of the study**

5 The randomised controlled trial aims to investigate the effect of the physical environment on the  
6 effect of exercise therapy and focuses on the significance of the context in which treatment is  
7 delivered.

8 The physical environment is a single component of the multifactorial concept of contextual effect  
9 and isolating only one component may be difficult as interaction between several components may  
10 occur.

11

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 INTRODUCTION

2 The physical environment affects the persons in it and may potentially be of significance for health  
3 and treatment effects. Studies on the role of physical environments conducted in hospital settings  
4 have reported that factors such as noise, daylight deprivation and light intensity may increase stress  
5 and pain level, reduce patient satisfaction and affect length of hospital stay<sup>1-5</sup>. Many rehabilitation  
6 and hospital exercise facilities are today located in large rooms in basements or other windowless  
7 rooms with poor acoustics, not designed for optimal exercise therapy delivery. These physical  
8 environments may affect patients negatively and potentially result in a poorer result from the  
9 exercise or rehabilitation, if patients are feeling unwelcomed or are not motivated to comply with  
10 the exercise in the given environment. Theoretically, enhanced physical environments may create  
11 positive atmosphere, enhance communication during exercise and potentially improve exercise  
12 performance, compliance and perceived wellbeing. Exercise is recommended as a life-long  
13 treatment for chronic diseases such as cardiovascular diseases, diabetes and musculoskeletal  
14 disorders, including hip and knee osteoarthritis (OA) and joint pain. Despite high-level evidence  
15 that exercise provides on average moderate pain relief and functional improvement in patients with  
16 osteoarthritis, large variation in effect is observed across studies and treatment effects may vary  
17 from small to large<sup>6, 7</sup>. In addition to differences in characteristics of the exercise programs studied,  
18 this may also relate to the fact that exercise interventions have been performed in different physical  
19 environments and that these environments may influence patients differently<sup>8</sup>. It is plausible, but  
20 currently unknown, whether the physical environment can be modified in ways, that enhances the  
21 effect of exercise therapy. To our knowledge, this is the first trial to actively investigate if  
22 modification of the physical environment can be used in a positive way to enhance the effect from  
23 exercise therapy.

24

1 This study applies the term ‘context effect’ as a framework for elucidating how treatment effect is  
2 potentially caused by a complexity of factors in addition to the actual treatment effect. Context  
3 effects are defined as the effects of a given treatment, not directly caused by the treatment itself, but  
4 rather caused by the context or environment in which the treatment is given<sup>8-11</sup>. Context effects may  
5 be considered as a parallel to placebo effects, which has been one of the most debated topics in  
6 modern medicine<sup>12-15</sup>. Several authors have objected to the term placebo, as they argue, that the  
7 definition is self-contradictory and inadequate<sup>9, 16-19</sup>. Placebo is in its classical term defined as  
8 giving an inert substance or treatment<sup>10, 18</sup>. However, if placebos are inert, they cannot have an  
9 effect, and if they have an effect, they cannot be inert<sup>9, 10, 16, 18</sup>. Other terms have been suggested,  
10 such as; non-specific effect, non-characteristic effect, incidental effects, meaning response, placebo  
11 components and context effects, as applied in this study<sup>9, 20-24</sup>. A clear distinction should be made  
12 between placebo effects and context effects. Placebo is associated with giving pills, injections or  
13 having surgery and often entails a form of deliberate deception, whereas context effects rather  
14 classify factors creating or enhancing a treatment effect<sup>8-11</sup>. Factors contributing to context effects  
15 can be divided into different categories, such as; characteristics of the patient and the practitioner,  
16 type of treatment, nature of disease and the physical environment<sup>8, 11</sup>. This study will focus on the  
17 physical environment where exercise therapy is delivered, as it can be modified in a standardised  
18 and reproducible way to potentially enhance adherence and enhance the positive effects of exercise  
19 therapy.

20  
21 The study aim is to investigate the effect of exercising in a contextually enhanced physical  
22 environment for 8 weeks for people with knee or hip pain. We hypothesize that, participants  
23 exercising according to a standardised program in a contextually enhanced physical environment  
24 will report greater improvement from exercise compared to participants following the same

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 exercising program in a standard physical environment as measured by patients' Global Perceived  
2 Effect (GPE). Further, we expect that the two exercise groups will be superior to a passive waiting  
3 list.

## 5 **METHODS AND ANALYSIS**

### 6 **Study design**

7 This study is designed as a 3-armed randomised controlled clinical trial. Participants are randomised  
8 to three intervention groups; exercise in a context enhanced physical environment (EX+ROOM),  
9 exercise in a standard physical environment (EX) or waiting list (WL). Participants, investigators  
10 and exercise instructors are blinded to treatment allocation. Primary endpoint is patient's global  
11 perceived effect assessed after 8 weeks exercise on a 7-point Likert scale. The Regional Scientific  
12 Ethical Committee for Southern Denmark has approved the study (study ID: S-20130130). It is  
13 consistent with the Helsinki Declaration and registered with [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (ID:  
14 NCT02043613). Results from this study will be reported according to the CONSORT statement<sup>25</sup>.

### 16 **Participants**

17 Eligible participants are 35 years or older, self-reporting persisting knee and/or hip pain within the  
18 last 3 months and are willing and able to attend exercise therapy twice weekly at the University of  
19 Southern Denmark, Odense M. Exclusion criteria are: 1) Co-morbidities or contraindication  
20 prohibiting participation in exercise therapy; 2) Inability to answer questionnaires or to speak, read  
21 or understand Danish; 3) Already participating in exercise therapy, defined as an exercise program  
22 supervised by a physiotherapist, or systematic training with duration of 6 weeks or more started  
23 within 3 months to inclusion, aimed specifically at relieving knee or hip joint problems; 4) Having  
24 had surgery to the hip/knee within the last 3 months or waiting for joint surgery in the coming 6



1 months. Participants are recruited via different pathways; posters and informational leaflets at  
general practitioners offices, the orthopaedic department at Odense University Hospital or  
participant initiated contact through posters and articles in local newspapers, social media and word  
of mouth (figure 1).

**Insert Figure 1 around here**

### **Intervention**

Participants are randomly assigned to one of three groups.

#### *Group EX+ROOM: exercise in contextually enhanced physical environment*

This exercise room is placed on the second floor in a newly build facility. It has a view to a newly  
reconstructed outdoor sport and recreational park. It has not prior been used in studies investigating  
exercise as a treatment option.

#### *Group EX: exercise in a standard physical environment*

This group will exercise in a room, which has been used in other exercise studies. The room is  
marked by years of use. It is placed in the basement and accessed through a series of staircases and  
hall-ways through the basement. This facility resembles many existing exercise facilities at  
hospitals and rehabilitation clinics and is considered a standard exercise environment.

#### *Contextual factors*

The physical environments are described and classified by a variety of contextual factors (**table 1**).

1  
2  
3  
4 1 Acoustic properties such as speech interpretability, reverberation and background noise are  
5  
6 2 measured by use of standard acoustic methods<sup>26</sup>. Better acoustic properties, such as shorter  
7  
8 3 reverberation time and higher speech interpretability, may reduce stress and improve  
9  
10 4 communication. In hospital environments high noise levels are associated with worse patient  
11  
12 5 outcomes such as psychological stress and satisfaction with care<sup>27</sup>. Background noise (dB(A)) is  
13  
14 6 measured in empty rooms. Reverberation is measured as T20, the time interval for a 20 dB decay  
15  
16 7 within a room. Reverberation is a measure of how long it takes for sound to decay in a room and a  
17  
18 8 long reverberation time affects speech comprehension negatively<sup>26</sup>. Reverberation and speech  
19  
20 9 interpretability are descriptive of how well speech is perceived in a room. Speech interpretability is  
21  
22 10 measured as speech clarity and transmission. Speech clarity is measured as a Clarity Index within  
23  
24 11 the initial 50ms (C50), it compares early sound reflection with later sound reflection. Early sound  
25  
26 12 reflections are positive for speech interpretability and later sound reflection will be perceived as  
27  
28 13 noise. A high C50 indicates good speech interpretability. Speech Transmission index (STI) is a  
29  
30 14 measure of sound quality in transmission from sound source to receiver. Reverberation and speech  
31  
32 15 interpretability are derived from tape recordings of loud clear noises emitted in the exercise rooms.  
33  
34 16 Acoustic measures are obtained from two positions in the room with small, medium and large  
35  
36 17 distance to the sound source. Light intensity is assessed using an adapted method from Walch et al,  
37  
38 18 2005. Light intensity is measured using a LUX meter (Amprobe, LM-100, light meter, Everett, WA,  
39  
40 19 USA) on two representative positions in the exercise rooms and additionally directly at windows, if  
41  
42 20 present in the room. Three consecutive measures are obtained from each position and averaged.  
43  
44 21 Light measurements are taken as close to the exercise time as possible. Daylight and brighter rooms  
45  
46 22 are associated with lower pain perception and lower postoperative analgesic intake in hospital  
47  
48 23 environments<sup>28, 29</sup>. Air quality is described by CO<sub>2</sub> concentration, temperature and air humidity in  
49  
50 24 the exercise rooms during exercise. Air quality is assessed with an air quality data logger, set to  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 collect data on 30 sec. intervals (Trotec, BZ-30, data logger, Heinsberg, Germany). Furthermore,  
 2 carefully selected pictures of nature scenes are hung in the contextually enhanced physical  
 3 environment. Viewing nature pictures or visual stimuli of nature elements have been known to  
 4 reduce stress in office setting and influence recovery time and decrease pain in patients following  
 5 surgery<sup>1, 5, 30-33</sup>.

7 **Table 1:** Descriptive environmental factors

Dimension	Factor	Contextually enhanced physical environment	Standard physical environment
Indoor environment	Light		
	- Strength (Lux)	@	@
	- Source	Daylight + artificial light	Artificial light.
	- Window/no window	Windows, Floor to ceiling	No windows
	Air quality		
	- CO <sub>2</sub> (ppm)	@	@
	- Temperature (°C)	@	@
	- Humidity (%)	@	@
	Sound/noise		
	- Background noise (dB(A))	@	@
	- Speech clarity (C50, STI)	@	@
	- Reverberation (T20)	@	@
Décor	Wall decorations	Picture of nature scenes	No decorations
	View	View of nature and outdoor exercise environment	No view

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Table 1: Parameters assessed in the different physical environments @ = assessed/measured and will be reported. Ppm:  
2 parts per million, C50, clarity index with first 50 ms of sound, STI: speech interpretability index, T20: reverberation  
3 time for sound decay of 20 dB.

#### 4 5 *Exercise*

6 The exercise program for participants in the EX+ROOM and EX group is based on the standardised  
7 NEuroMuscular EXercise (NEMEX) program. It is described in detail elsewhere<sup>34</sup> and has  
8 previously been investigated for feasibility in patients with severe knee or hip OA<sup>34</sup>. The NEMEX  
9 program is based on biomechanical and neuromuscular principles, which aim to improve  
10 sensorimotor control and achieve functional stability<sup>34</sup>. The NEMEX program has previously been  
11 shown to be effective to relieve pain and improve function in populations with knee or hip pain  
12 such as anterior cruciate ligament injuries<sup>35-38</sup>, meniscectomized participants<sup>39, 40</sup> patients with hip  
13 or knee OA undergoing total joint arthroplasty<sup>34, 41</sup>. Exercise is performed as group exercise and all  
14 exercise sessions are supervised. All instructors will be certified in the NEMEX program. To ensure  
15 consistency between instructors, they will participate in a two-day course, Good Life with  
16 osteoarthritis in Denmark, focusing on lower-limb osteoarthritis management and neuromuscular  
17 exercise. After completing the course all instructors will go through the exercise program with the  
18 primary investigator to ensure consistency in instructing and supervising exercise as well as going  
19 through how volume, load and progression of exercise and pre- and post-exercise pain should be  
20 documented in participants' exercise dairies. The EX+ROOM and EX group will exercise on the  
21 same weekdays, twice a week for one hour duration. An instructor will first supervise the  
22 EX+ROOM group and then the EX group. Consequently, all of the instructors will have supervised  
23 the NEMEX program in both physical environments and for the same amount of time, i.e. if an  
24 instructor supervises the EX+ROOM group then they supervise the EX group as well. This is done  
25 to ensure consistency in delivery instructions and supervision of exercise across study participants

1 and to ensure that any effect that a given instructors may have on the exercise and participants  
2 should be similar between physical environments.

3  
4 *Group WL: waiting list/control group*

5 Participants randomised to waiting list are placed on a passive waiting list for a period of 8 weeks,  
6 and thereafter offered 8 weeks of structured resistance exercise. These participants act as an  
7 observational group and represent the natural course of disease in participants with knee and/or hip  
8 pain. After the 8 weeks when follow-up data for the current study has been collected, the  
9 participants are offered resistance exercise rather than neuromuscular exercise for logistic reasons,  
10 such as avoiding taking up place in the designated exercise rooms used in the study and  
11 consequently affecting the time to completion of the study.

12  
13 **Primary outcome**

14 Participants' Global Perceived Effect (GPE) assessed at 8 weeks will be the primary endpoint of the  
15 trial. Participants are asked to respond to the following question; "*Compared to before you entered*  
16 *the study, how are your knee/hip problems now?*" on a 7-point Likert scale. The GPE scale ranges  
17 from 'markedly worse' through 'no change' to 'markedly improved'. GPE is a reliable method for  
18 measuring the effect of clinical interventions<sup>42, 43</sup>. It has prior been used in studies investigating  
19 contextual effect of treatment<sup>44</sup>. The validity of GPE scales has been questioned. However, a study  
20 on the correlation between transition ratings and pre and post score of quality of life questionnaires  
21 showed a correlation of 0.8 between the change score of the questionnaire and the transition ratings  
22 suggesting that transition scales, such as global perceived effects, are valid for detecting changes  
23 and can be used in clinical trials as primary outcome measures<sup>43</sup>.

1  
2  
3  
4 **1 Secondary outcomes**

5  
6 2 All outcomes and time points for data collection are listed in **table 2**.

7  
8  
9 3

10  
11 4 **Table 2:** Summary of collected data and time points

Variable	Baseline	4 weeks	8 weeks
<b>Baseline data</b>			
Height (cm)	@	n.a.	@
Weight (kg)	@	n.a.	@
Age (yrs.)	@	n.a.	n.a.
Gender ( f/m)	@	n.a.	n.a.
Marital status	@	n.a.	n.a.
Educational level	@	n.a.	n.a.
Employment status	@	n.a.	n.a.
Alcohol consumption	@	n.a.	n.a.
Smoking	@	n.a.	n.a.
Physical activity level at work and leisure	@	n.a.	n.a.
<b>Primary outcome</b>			
Global Perceived Effect (7 point Likert scale).	n.a.	@	@
<b>Secondary outcomes</b>			
<b>Patient reported outcomes</b>			
Knee/Hip Injury and Osteoarthritis Outcome Score	@	@	@
Short-form 36 Health Survey	@	@	@
Modified Arthritis Self-Efficacy Scale	@	@	@
Patient Acceptable Symptom State (y/n)	n.a.	n.a.	@
Patient satisfaction (5 point Likert scales).	n.a.	n.a.	@
Stress (100 mm VAS)	@	n.a.	@

Objective physical function tests			
Aerobic capacity (ml O <sub>2</sub> /min/kg)	@	n.a.	@
Isometric strength hip abduction (Nm)	@	n.a.	@
Isometric strength knee extension (Nm)	@	n.a.	@
Single-limb mini squat	@	n.a.	@
Knee bends/30 sec. (no.)	@	n.a.	@
Chair stands/30 sec. (no.)	@	n.a.	@
Walking test, 40 m fast paced. (sec)	@	n.a.	@
One-leg hop of distance (cm)	@	n.a.	@

Table 2: Summary of primary and secondary outcomes and respective time collection points, @ = assessed/measured, n.a. = not assessed VAS: visual analogue scale.

#### *Patient reported outcomes*

Participants answer the Danish versions of the Knee injury and Osteoarthritis Outcome Score (KOOS) or The Hip disability and Osteoarthritis Outcome Score (HOOS) depending on either knee or hip problems being primary complaint. The KOOS and the HOOS are joint-specific questionnaires, developed to assess participants' opinion about their knee or hip problems<sup>45, 46</sup>. KOOS/HOOS consists of 5 subscales; pain, symptoms, activities of daily life function, sport and recreational function and joint related quality of life<sup>47</sup>. Each subscale consists of a set of items specific to the subscale and each item is assessed via a Likert scale with 5 possible answer options ranging from 0 (no problems) to 4 (extreme problems). The Likert score is transformed to a 0-100 scale with zero representing extreme knee problems and 100 representing no knee problems<sup>45</sup>. KOOS and HOOS have good psychometric properties for patient groups with knee injury, knee replacement, hip dysfunction and hip replacement<sup>46-50</sup>.

1 The Medical Outcome Study 36-item short form general health survey (SF-36) is a generic patient-  
2 reported health status measure<sup>51-53</sup>. It consists of 36 items organised under 8 subscales; 1) physical  
3 functioning, 2) role limitations because of physical health, 3) bodily pain, 4) social functioning, 5)  
4 general mental health, 6) role limitations because of emotional problems, 7) vitality, and 8) general  
5 health perception<sup>53</sup>. Low scores indicate limitations in activities and a perception of poor health,  
6 high score indicate no limitations and good health<sup>53</sup>. Validity and reliability of the SF-36 is  
7 adequate and the questionnaire is widely used<sup>51, 52</sup>.

8 A modified measure of self-efficacy is included to evaluate patients' perception of functionality or  
9 limitations to their functionality caused by their knee or hip problem. Self-efficacy is defined by  
10 Bandura as "belief in one's capability to organise and execute the course of action required to  
11 produce given attainments<sup>54</sup>. Self-efficacy is assessed with a modified version of the Arthritis Self-  
12 Efficacy Scale (ASES)<sup>55</sup> previously used in a similar patient group<sup>56</sup>. The modified version of  
13 ASES consists of 11 single items from the two subscales pain and other symptoms. Participants rate  
14 their ability to cope with pain and symptoms related to their joint problem, on a 10-100 scale, with  
15 10 indicating very uncertain and 100 indicating very certain with 10 point increments<sup>57</sup>.

16 Patient reported outcomes are collected using an online survey. At baseline and 8 weeks follow-up  
17 participants answer the survey on a computer in the examination room without the investigator  
18 present. At 4-week follow-up an email is sent to participants, who answer at home. To ensure high  
19 data completion an email reminder is sent, if no reply is received within 3-5 days. Further,  
20 participants are called by phone if there is no reply to the reminder e-mail.

21 A series of single item questions are included. Patient Acceptable Symptom State is assessed by  
22 asked a single yes/no question; "Considering your knee function, do you feel that your current state  
23 as satisfactory? With knee function you should *take into account all the activities you have during*  
24 *your daily life, your level of pain and other symptoms and your quality of life*"<sup>58</sup>. If participants rate



1 their current symptom state as unacceptable, a follow-up question is asked as to if they consider the  
2 treatment to have failed. Further, participants are asked to answer five global perceived effects  
3 questions specific for each of the five subscales of either KOOS or HOOS, rating either  
4 improvement or deterioration and finally an indication of whether these changes are perceived as  
5 important or unimportant by the participants. These single items are included in order to assess  
6 minimal clinically important changes for the five subscales of the KOOS and HOOS. Stress is  
7 estimated as 'general stress level' measured on a 100 mm visual analogue scale ranging from no  
8 stress to stress as severe as could be<sup>59</sup>.

#### 10 *Functional performance*

11 Patients' aerobic capacity is estimated during a submaximal work rate bicycle test<sup>60</sup>. Patients pedal  
12 until reaching a steady state, with a stable pulse rate ranging between 120 to 170 beats per minute,  
13 normally within 6-7 minutes<sup>60</sup>. Participants' aerobic capacity is estimated from work rate and  
14 stable pulse rate by use of Åstrand's Nomogram<sup>60</sup>.

15 Maximal isometric knee extension and hip abduction strength will be tested using dynamometry  
16 (JTECH medical, Commander Echo, Salt Lake City, Utah, USA). A suction cup is mounted on a  
17 door behind the examination couch. A strain gauge, measuring pull in newton, is placed in between  
18 the suction cup and a fixation belt strapped around the participant's ankle above the lateral malleoli.  
19 For knee extension, participants sit on an examination couch with a hip angle of 90° and a knee  
20 angle of 90°. Participants are asked to press against their foot the belt in a forward motion. The  
21 distance from the knee joint axis to the middle of the fixation belt is measured. Consequently,  
22 isometric muscle strength is measured as torque. For hip abduction, participants lie on the couch  
23 with their leg straight and are asked to press their lateral malleoli against the belt. The distance from  
24 the trochanter major on the femoral bone to the middle of the fixation belt is measured. One practice

1 trial is allowed and thereafter three maximal contractions are performed separated by a 60 sec.  
2 pause. Isometric muscle strength is normalised to body weight to increase comparability. The  
3 methods for assessing isometric muscle strength have been adapted from Thorborg et al. who  
4 reported good inter-tester reliability with an interclass correlation coefficient ranging from 0.76 –  
5 0.95 and standard error of measurement between 5.0% to 10.4% for hip and knee strength  
6 assessments<sup>61</sup>.  
7 Physical function is assessed by 5 performance tests; 1) single limb mini squats<sup>62</sup>, 2) number of  
8 knee bendings on one leg during 30 sec standing<sup>63, 64</sup>, 3) number of chair stands during 30 sec<sup>65, 66</sup>,  
9 4) 40 m fast-paced walking test<sup>65</sup> and 5) one leg hop for distance<sup>63</sup>. All performance tests have been  
10 found valid to assess lower extremity function in different patient groups with knee or hip  
11 problems<sup>63, 66-68</sup>. As large variation regarding age and function within participants of this trial is  
12 expected, and therefore a test battery with a wide range of difficulty of the performance tests is  
13 chosen to ensure that all participants would be challenged. A floor effect may be evident in the one  
14 leg hop for distance test as some participants may not be able to hop at all. No ceiling effects are  
15 expected for any of the functional performance measures.

### 17 **Explanatory outcomes and nested qualitative study**

18 To investigate how the physical environment and other potential context factors, such as participant  
19 and practitioner interaction and behaviour, may interact and mediate the treatment effects,  
20 explanatory outcomes are included. Explanatory outcomes have been selected to explain the process  
21 by which context effects work and possibly elucidate which elements within the physical  
22 environment that enhance treatment effects and how these elements affect the patients and  
23 practitioners. A qualitative study will be embedded within the randomised controlled trial design.  
24 The aim of the qualitative study is to investigate, how the participants experience the two different

1 physical environments. Observation is performed in both rooms during exercise sessions to describe  
2 and identify behaviour of practitioners and participants specific to the different physical  
3 environments. Focus group interviews will be conducted with participants to investigate their  
4 experiences with the exercise environments and to invite participants to articulate and elaborate on  
5 their thoughts on how the physical environment has affected them. Three focus group interviews  
6 will be conducted with a total of 10 to 20 participants from the contextually enhanced physical  
7 environment and 3 focus group interviews with similar number of participants from the standard  
8 physical environment, i.e. 6 focus groups in total. Participants invited to the focus groups will be  
9 those randomized to exercise in the RCT design (group EX+ROOM and group EX). The interviews  
10 will be transcribed and analysed using thematic coding comparing within and across the different  
11 physical environments. Additionally, in-depth individual interviews will be performed with 6  
12 participants. To ensure the blinding of participants throughout the study all interviews will be  
13 conducted after the intervention and after follow-up testing has been completed.  
14 Additionally, a patient reported outcome 'participant satisfaction' is reported as participants'  
15 satisfaction with the exercise intervention in itself as well as satisfaction with specific contextual  
16 factors within the physical environment. Eleven single items scoring the different factors of the  
17 physical environment such as lighting, cleanliness, access, decoration etc. are administered to  
18 participants in intervention groups EX+ROOM and EX. The items are adapted from Tsai et al.<sup>69</sup>.  
19 Satisfaction is scored on a 5-point Likert scale ranging from 1 to 5 (1=strongly dissatisfied,  
20 2=dissatisfied, 3=fair, 4=satisfied, and 5=strongly satisfied).

## 21 22 **Compliance and adverse events**

23 In the two exercise groups, compliance is considered good at 75% or if 12 of 16 possible exercise  
24 sessions are attended. Participants in the WL group are asked at 8 weeks follow-up, whether they

1 have started any exercise courses with the last 8 weeks. If answering yes, they are asked to describe  
2 the change. This is done in order to account for compliance to the waiting list design. Self-reported  
3 adverse events occurring in-between exercise sessions are recorded at 4 and 8 weeks in the online  
4 survey. Adverse events are defined as any events that the participants found restricting them  
5 physically, mentally or socially. Participants also indicate whether of they have been in contact with  
6 either their general practitioner or the hospital in relation to their adverse event. Any adverse events  
7 occurring during the exercise sessions are recorded by the supervising instructors.

### 9 **Randomisation**

10 Randomisation is performed immediately after baseline assessment and is administered by a  
11 research coordinator, not otherwise involved in the study. Patients are consecutively assigned and  
12 given a numbered, sealed, opaque envelope entailing treatment allocation. The randomisation  
13 sequence is computer-generated and prepared by a statistician with no clinical involvement in  
14 conducting the trial. To avoid imbalances in treatment allocation among people with knee and hip  
15 pain, two block randomisation lists were computer-generated (with a 2:2:1 allocation). The block  
16 size is kept secret to maintain blinding; each block consisted of either 5 or 10 patients. The  
17 randomisation lists and envelopes are kept in a secure location at the university.

### 19 **Blinding procedure**

20 Participants are blinded to the study aim in order to avoid excess focus on the physical environment,  
21 which potentially could exaggerate context effects from the physical environment. Participants are  
22 therefore informed that they are participating in a study evaluating the effects from exercise  
23 compared to being on a waiting list and are not made aware that the true aim of the study is to  
24 investigate the possible additional effect from an enhanced physical environment on exercise. The

1 instructors supervising the exercise sessions are neither informed about the true aim of the study.  
2 However, they are aware that exercise sessions are performed in different rooms as they supervise  
3 sessions in both rooms. The instructors have been informed that the different exercise rooms are  
4 used for practical and logistic reasons. The primary investigator conducting baseline and follow-up  
5 testing is also blinded to treatment allocation and participants are instructed to not to speak about  
6 the intervention with the investigator, thereby keeping blinding intact.

### 8 **Sample size estimation and power considerations**

9 This study is designed as a superiority trial with three groups (EX+ROOM, EX and WL). Since this  
10 is the first study to investigate the additional effect of an enhanced physical environment on the  
11 effect of exercise therapy as treatment for knee or hip pain, there are no previous data to base our  
12 sample size estimation on. Thus the power calculation is based on factors such as feasibility, i.e.  
13 how many participants will be realistic to include with the recruitment period and pragmatic issues  
14 such as availability and capacity of the different exercise rooms. Taking these aspects into  
15 consideration 100 participants will be included into the trial. To be able to account for the natural  
16 disease progression or regression towards the mean the waiting list (WL) is included in the design.  
17 A randomisation with a 2:2:1 allocation is chosen and thus 40 participants are randomised to  
18 EX+ROOM and EX groups, respectively, and 20 participants are randomised to the WL group. We  
19 anticipate that individuals in the WL group will experience limited effect. With 40 subjects in each  
20 of the two exercise groups (EX+ROOM and EX), we are able to detect a difference of 0.75 on the  
21 GPE scale ranging from -3 to 3 with a standard deviation of 1.2, a p-value of 0.05 and a power of  
22 80%.

### 24 **Statistical evaluation**

1  
2  
3  
4 1 All three intervention groups (EX+ROOM, EX and WL) will be examined for comparability at  
5  
6 2 baseline with respect to demographic factors using ANalysis Of VAriance (ANOVA) and Chi-  
7  
8 3 squared test as appropriate.  
9  
10 4 The primary analysis on the GPE data will be conducted with a Student's unpaired t-test comparing  
11  
12 5 the EX+ROOM intervention group with EX intervention group at the 8-week follow-up. The  
13  
14 6 Bonnet-Price median test will be conducted if assumption of normality in the GPE data is not  
15  
16 7 supported. The WL intervention group is considered a reference group describing the natural  
17  
18 8 progression of disease for the included study population and is not included in the primary analysis.  
19  
20 9 However, to check the general assumption, that exercise is more effective than no intervention, an  
21  
22 10 unpaired t-test is conducted to compare the exercise groups with the waiting list.  
23  
24 11 The secondary outcomes, the KOOS/HOOS, SF-36, ASES and physical function outcomes are  
25  
26 12 analysed as repeated measures (i.e. change from baseline over 4 and 8 weeks follow-up for patient  
27  
28 13 reported outcomes and baseline to 8 week follow-up for physical function tests) applying a mixed  
29  
30 14 linear effects model with 'participant' as random effect and sex, age and joint as fixed effects. As  
31  
32 15 for the primary outcome, only the EX+ROOM and EX groups are compared. Additionally, to test  
33  
34 16 an *a priori* hypothesis of a graded relationship between groups EX+ROOM > EX > WL a linear test  
35  
36 17 for trend will be conducted as an explanatory analysis on all outcomes. Here, a  $\chi^2$  test for trend is  
37  
38 18 applied for dichotomous outcomes and a linear test for trend is applied for continuous outcomes.  
39  
40 19 Pairwise comparison of groups will be conducted if the trend test was significant, to describe the  
41  
42 20 association between group and outcome, i.e. EX+ROOM vs EX and EX vs WL. For dichotomised  
43  
44 21 outcomes a  $\chi^2$  test is applied, and for continuous ANOVA is applied.  
45  
46 22 Intention-to-treat analysis is performed and last observation is carried forward for missing data at  
47  
48 23 follow-up for the secondary outcomes. The primary outcome is a transition score, which is not  
49  
50 24 assessed as baseline. For any participants lost to follow-up GPE data will be missing. Further, a per-  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 protocol analysis is conducted including only those with good compliance with the exercise  
2 intervention (participated in at least 12 of 16 sessions) in the EX+ROOM and EX groups,  
3 respectively.

4 A detailed statistical analysis plan will be drafted and made publicly available before breaking  
5 randomisation code and conducting data analysis. To further minimise the risk for bias introduced  
6 during analysis and interpretation, data analysis will be performed by a third party not otherwise  
7 related to the study. Intervention groups will be allocated with arbitrary names. Interpretation will  
8 be performed by the primary investigator in collaboration with the research team prior to revealing  
9 treatment allocation, thereby interpreting the results blindly<sup>70</sup>. Consequently, two interpretation  
10 scenarios will be drafted on the basis of the primary outcome data, i.e. comparing treatment A with  
11 treatment B. One assuming that group A will be the EX+ROOM group and another assuming that A  
12 will be the EX group.

## 13 **ETHICS AND DISSEMINATION**

14 Context effects may constitute an important part of the effects of exercise therapy. Investigating  
15 context effects will provide knowledge on how the physical environment may be exploited to  
16 enhance the effects of exercise therapy in addition to the effect of the specific exercise. Exercise is  
17 an effective and widely used core treatment strategy for chronic diseases, such as musculoskeletal  
18 disorders, cardio vascular disease and diabetes. Adding to the effect of exercise through context  
19 effects from a contextually enhanced physical environment in exercise facilities may be highly  
20 beneficial for patients across a number of diseases.

21  
22  
23 Previous research in context effects from physical environments has been conducted in hospital  
24 settings<sup>27</sup>. A comprehensive review from 2008 showed that certain elements within a hospital



1 context such as noise and lighting level have impact on number of medical errors as well as  
2 increased pain and stress levels for patients and staff<sup>27</sup>. Research in other health care settings has  
3 been sparse. During an initial literature review only one study was identified investigating physical  
4 therapy and its relation to the physical environment. The literature review comprised groups of  
5 search terms for context effects, exercise/physical therapy and terms for physical environments.  
6 Articles were search for in Medline, Scopus and single specific journals such as Health  
7 Environment Research and Design journal. When reviewed, this single study used observation,  
8 surveys and interviews to learn more about the design of a hospital roof-top garden rather than  
9 investigating if the physical environment had an additional effect on the physical therapy<sup>71</sup>. Further,  
10 the therapy of the study was described as activities including gardening, golf putting and events  
11 such as concerts or barbeques, not regular exercise. Consequently, this is to our knowledge the first  
12 study investigating if there is an effect from an enhanced physical environment in addition to  
13 exercise when compared to exercise performed in a standard setting.

14  
15 The three-armed RCT design of the present study has several advantages. It has been widely  
16 discussed whether the placebo effect can be explained by spontaneous remission or regression  
17 towards the mean<sup>15, 72-74</sup>. To rule out either of these as explanatory factors of a possible effect, the  
18 waiting list group is included into the design as an untreated reference group. The waiting list group  
19 illustrates the natural course of disease for the study population during the study period.  
20 Consequently, if a difference is seen between the two exercise rooms, the waiting list group enables  
21 an assessment of whether the difference is caused by spontaneous remission by comparing the  
22 exercise groups to the waiting list. To optimise the number of study participants, a 2:2:1 allocation  
23 with half the number of participants allocated to the waiting list is chosen. The three-armed design



1 also allows for a test for trend across groups. This form of analysis has been previously applied in a  
2 study investigating context effects originating from patient and practitioner interaction<sup>44</sup>.

3  
4 Context effects are a multifactorial concept and several factors, other than the physical  
5 environment, may contribute to the context effect of a given treatment. Literature reviews on  
6 context effect have additionally suggested factors, such as characteristics of patients/participants,  
7 practitioner/instructors or treatment and nature of disease as potentially contributing to the total  
8 context effect and theoretically, components may interact and possibly have synergistic effects<sup>8, 9, 16,</sup>  
9 <sup>24, 75</sup>. Especially the interaction between patient and practitioner has been suggested as a significant  
10 contributor to context effects<sup>44, 76-85</sup>. In a recent study, Kaptchuk et al. found, that patients with  
11 irritable bowel syndrome, who were treated by a warmer and friendlier practitioner, had  
12 significantly better results from sham-acupuncture, than patients treated by a practitioner, who  
13 limited eye-contact and avoided conversation<sup>44</sup>. Similarly, Suarez-Almazor et al. found that knee  
14 osteoarthritis patients treated with sham-acupuncture by a practitioner, who expressed high  
15 expectations to the treatment, had better outcomes than those treated by a practitioner with a neutral  
16 position towards treatment effects<sup>83</sup>. Although the interaction between patient and practitioner is  
17 suggested as the most robust component of context effect, behaviour, communication and  
18 interaction between patient and practitioner is difficult to change and may be hard to reproduce. An  
19 advantage in exploiting the potential context effect from the physical environment is that, the  
20 components of the environment can be thoroughly described and more easily implemented or  
21 changed in existing exercise environments.

22  
23 There are some limitations to the study design that must be acknowledged. The multifactorial  
24 concept of context effects questions whether the physical environment can be isolated and studied

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 alone. Several actions are taken to isolate the physical environment as the only difference between  
2 groups in this trial. The exercise program is standardised and delivered in a group fashion by the  
3 same instructors and all instructors have supervised in both physical environments. Consequently,  
4 treatment characteristics are similar between the intervention groups. Participants' characteristics,  
5 known and unknown, should be equally distributed between groups as a result of the randomisation  
6 process. Any specific characteristics that may origin from the instructor or from instructor-  
7 participant interaction should also be comparable between groups, as instructors supervise in both  
8 rooms.

9 Additionally, the nested qualitative study is aimed to investigate how the physical environment may  
10 affect behaviour of the participants or instructors or the interaction between them. The study will  
11 elucidate these issues and help explain the process of how a standard and enhanced physical  
12 environment affects participants and instructors.

13  
14 The primary ethical concern in this study is that the true aim of the study is withheld from  
15 participants. Withholding the aim disables participants to consider the implications of the research  
16 and to assess whether or not they want to contribute to investigating this aim. However, blinding the  
17 true aim is imperative to the study design as an effect from the physical environment may be over-  
18 or underestimated, if participants are explicitly made aware of the actual aim of the study.

19 Participants are therefore told that the study is designed to investigate the effect of neuromuscular  
20 exercise as an early treatment strategy for musculoskeletal pain. Similarly the supervising  
21 instructors are also blinded to the true aim of the study. Instructors are aware that the exercise is  
22 performed in different environments, but are told this due to logistic reasons. The ethics committee  
23 has been explicitly made aware that study participants and instructors are not made aware of the  
24 true study aim and despite this sanctioned the study without any reservations or conditions.

1 This study is designed to investigate the significance of the physical environment for the effects of  
2 exercise therapy and rehabilitation. The design of the study is novel and the results will provide  
3 knowledge on the significance of creating an optimal context for exercise therapy. Further studies  
4 investigating context effects of treatment are warranted to further enhance treatment effects.  
5

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60**1 List of abbreviations used**

2 CONEX: CONtext effect in EXercise.

3 RCT: Randomised Controlled Trial

4 OA: OsteoArthritis

5 GPE: participant's Global Perceived Effects.

6 EX+ROOM: EXercise in a context enhanced physical environment

7 EX: EXercise in a standard physical environment.

8 WL: waiting list

9 T20: Time for 20dB decay

10 C50: Clarity index, for initial 50 ms.

11 STI: Speech Interpretability Index

12 NEMEX: NEuroMuscular EXercise.

13 KOOS: the Knee Osteoarthritis and injury Outcome Score

14 HOOS: the Hip disability and Osteoarthritis Outcome Score

15 SF-36: Short-Form (36 item) Health Survey

16 ASES: Arthritis Self-Efficacy Scale

17 MVC: Maximal Voluntary Contraction.

18 ANOVA: ANalysis Of VARIation

19

**20 Acknowledgements**

21 Peter Møller Juhl, MSc EE, PhD, Associate Professor for assisting in measuring acoustic properties,

22 and Anne Marie Rosager for invaluable help during the randomisation process. The funding sources

23 had no role in the design of this study and will not have any role during its execution, analyses,

24 interpretation of the data, or decision to submit results.

1

**2 Funding**

3 The study is supported by The Swedish Research Council (2006-4129) and the Faculty of Health at  
4 University of Southern Denmark for funding LFS' salary, and the Danish Rheumatism Association  
5 for supporting the study with a grant (May, 2013).

6

**7 Competing interests**

8 *The listed author(s) have no competing interests to declare.*

9

**10 Author's contributions**

11 LFS, JBT, RU, PD and ER were involved in the design of the study. All authors contributed to  
12 drafting the manuscript or revising it. All authors read, commented and approved the manuscripts  
13 for publication.

14

**15 Author affiliation**

16 LFS: MSc, PhD student, Research Unit for Musculoskeletal Function and Physiotherapy at the  
17 Department of Sports Science and Clinical Biomechanics, University of Southern Denmark,  
18 Odense, Denmark.

19 JBT: MSc, PhD, Associate Professor; Research Unit for Musculoskeletal Function and  
20 Physiotherapy at the Department of Sports Science and Clinical Biomechanics, University of  
21 Southern Denmark, Odense, Denmark.

22 RU; PhD, Professor, Chalmers University of Technology, Gothenburg, Sweden

23 PD; MD, Professor, University of Exeter Medical School, Exeter, UK

1 ER: PT, PhD, Professor, Research Unit for Musculoskeletal Function and Physiotherapy at the  
2 Department of Sports Science and Clinical Biomechanics, University of Southern Denmark,  
3 Odense, Denmark.

#### 4 5 **Figure legend**

6 Figure 1: Flow chart, overview of the recruitment flow in the CONEX trial.  
7

#### 8 **References**

- 9
- 10 1. Ulrich R. View through a window may influence recovery from surgery. *Science* 1984;**224**(4647):420-21.
- 11 2. Ulrich R, Simons RF, Losito BD, et al. Stress recovery during exposure to natural and urban  
12 environments. *Journal of environmental psychology* 1991;**11**:201-30.
- 13 3. Parish JT, Berry LL, Lam SY. The effect of the servicescape on service workers. *J Serv Res-U*  
14 2008;**10**(3):220-38.
- 15 4. Malenbaum S, Keefe FJ, Williams AC, et al. Pain in its environmental context: implications for designing  
16 environments to enhance pain control. *Pain* 2008;**134**(3):241-4.
- 17 5. Kweon BS, Ulrich RS, Walker VD, et al. Anger and stress - The role of landscape posters in an office  
18 setting. *Environment and Behavior* 2008;**40**(3):355-81.
- 19 6. Fransen M, McConnell S, Bell M. Therapeutic exercise for people with osteoarthritis of the hip or knee. A  
20 systematic review. *The Journal of Rheumatology* 2002;**29**(8):1738-46.
- 21 7. Fransen M, McConnell S. Land-based exercise for osteoarthritis of the knee: a metaanalysis of  
22 randomized controlled trials. *J Rheumatol* 2009;**36**(6):1109-17.
- 23 8. Di Blasi Z, Harkness E, Ernst E, et al. Influence of context effects on health outcomes: a systematic  
24 review. *The Lancet* 2001;**357**(9258):757-62.
- 25 9. Miller FG, Kaptchuk TJ. The power of context: reconceptualizing the placebo effect. *J R Soc Med*  
26 2008;**101**(5):222-5.

10. Koshi EB, Short CA. Placebo theory and its implications for research and clinical practice: A review of the recent literature. *Pain practice : the official journal of World Institute of Pain* 2007;**7**(1):4-20.
11. Kaptchuk TJ. The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance? *Ann Intern Med* 2002;**136**(11):817-25.
12. Beecher HK. The Powerful Placebo. *Jama-J Am Med Assoc* 1955;**159**(17):1602-06.
13. Miller FG, Rosenstien DL. The nature and power of the placebo effect. *J Clin Epidemiol* 2006;**59**(4):331-5.
14. Hrobjartsson A. The uncontrollable placebo effect. *Eur J Clin Pharmacol* 1996;**50**(5):345-8.
15. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. *The New England journal of medicine* 2001;**344**(21):1594-602.
16. Barrett B, Muller D, Rakel D, et al. Placebo, meaning, and health. *Perspect Biol Med* 2006;**49**(2):178-98.
17. Breidert M, Hofbauer K. Placebo: Misunderstandings and prejudices. *Deutsches Arzteblatt international* 2009;**106**(46):751-55.
18. Margo CE. The placebo effect. *Surv Ophthalmol* 1999;**44**(1):31-44.
19. Grunbaum A. The Placebo Concept. *Behav Res Ther* 1981;**19**(2):157-67.
20. Doherty M, Dieppe P. The "placebo" response in osteoarthritis and its implications for clinical practice. *Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society* 2009;**17**(10):1255-62.
21. Paterson C, Dieppe P. Characteristic and incidental (placebo) effects in complex interventions such as acupuncture. *BMJ* 2005;**330**(7501):1202-5.
22. Dellmann T, Lushington K. How can complementary medicine practitioners enhance non-specific effects? *journal of the Australian Traditional-Medicine Society* 2008;**14**(1):13-17.
23. Dieppe P, Doherty M. Contextualizing osteoarthritis care and the reasons for the gap between evidence and practice. *Clin Geriatr Med* 2010;**26**(3):419-31.
24. Moerman DE, Jonas WB. Deconstructing the placebo effect and finding the meaning response. *Ann Intern Med* 2002;**136**(6):471-6.
25. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMC Med* 2010;**8**.

- 1  
2  
3  
4 1 26. Kuttruff H. *Room acoustics*. London: Spon Press, 2000.
- 5  
6 2 27. Ulrich RS, Zimring C, Zhu XM, et al. A Review of the Research Literature on Evidence-Based  
7  
8 3 Healthcare Design. *Herd-Health Env Res* 2008;**1**(3):61-125.
- 9  
10 4 28. Shepley MM, Gerbi RP, Watson AE, et al. The Impact of Daylight and Views on ICU Patients and Staff.  
11  
12 5 *Health Environments Research & Design Journal (HERD)* 2012;**5**(2):46-60.
- 13  
14 6 29. Walch JM, Rabin BS, Day R, et al. The effect of sunlight on postoperative analgesic medication use: A  
15  
16 7 prospective study of patients undergoing spinal surgery. *Psychosom Med* 2005;**67**(1):156-63.
- 17  
18 8 30. Ulrich RS. Human Responses to Vegetation and Landscapes. *Landscape Urban Plann* 1986;**13**(1):29-44.
- 19  
20 9 31. Ulrich RS. Natural Versus Urban Scenes - Some Psychophysiological Effects. *Environment and*  
21  
22 10 *Behavior* 1981;**13**(5):523-56.
- 23  
24 11 32. Tse MMY, NG JKF, Chung JWY, et al. The effect of visual stimuli on pain threshold and tolerance. *J*  
25  
26 12 *Clin Nurs* 2002;**11**:462-69.
- 27  
28 13 33. Diette GB, Lechtzin N, Haponik E, et al. Distraction therapy with nature sights and sounds reduces pain  
29  
30 14 during flexible bronchoscopy: a complementary approach to routine analgesia. *Chest*  
31  
32 15 2003;**123**(3):941-8.
- 33  
34 16 34. Ageberg E, Link A, Roos EM. Feasibility of neuromuscular training in patients with severe hip or knee  
35  
36 17 OA: the individualized goal-based NEMEX-TJR training program. *BMC Musculoskelet Disord*  
37  
38 18 2010;**11**:126.
- 39  
40 19 35. Zätterström R, Friden T, Linstrand A, et al. Early rehabilitation of acute anterior cruciate ligament injury  
41  
42 20 - a randomized clinical trial. *Scand J Med Sci Sports* 1998(8):154-59.
- 43  
44 21 36. Ageberg E, Zätterström R, Moritz U, et al. Influence of Supervised and Nonsupervised Training on  
45  
46 22 Postural Control After an Acute anterior Cruciate Ligament Rupture: A Three-year Longitudinal  
47  
48 23 Prospective Study. *J Orthop Sports Phys Ther* 2001;**31**(11):632-44.
- 49  
50 24 37. Ageberg E. Consequences of a ligament injury on neuromuscular function and relevance to rehabilitation  
51  
52 25 - using the anterior cruciate ligament injured knee as model. *J Electromyogr Kinesiol* 2002;**12**:205 -  
53  
54 26 12.
- 55  
56  
57  
58  
59  
60




- 1  
2  
3  
4 1 38. Zätterström R, Friden T, Lindstrand A, et al. Muscle training in chronic anterior cruciate ligament  
5  
6 2 insufficiency--a comparative study. *Scand J Rehabil Med* 1992;**24**(2):91-7.  
7  
8 3 39. Roos EM, Dahlberg L. Positive effects of moderate exercise on glycosaminoglycan content in knee  
9  
10 4 cartilage: a four-month, randomized, controlled trial in patients at risk of osteoarthritis. *Arthritis*  
11  
12 5 *Rheum* 2005;**52**(11):3507-14.  
13  
14 6 40. Ericsson YB, Dahlberg LE, Roos EM. Effects of functional exercise training on performance and muscle  
15  
16 7 strength after meniscectomy: a randomized trial. *Scand J Med Sci Sports* 2009;**19**(2):156-65.  
17  
18 8 41. Villadsen A, Overgaard S, Holsgaard-Larsen A, et al. Postoperative effects of neuromuscular exercise  
19  
20 9 prior to hip or knee arthroplasty: a randomised controlled trial. *Ann Rheum Dis* 2013.  
21  
22 10 42. Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses  
23  
24 11 and considerations for design. *J Man Manip Ther* 2009;**17**(3):163-70.  
25  
26 12 43. Guyatt GH, Norman GR, Juniper EF, et al. A critical look at transition ratings. *J Clin Epidemiol*  
27  
28 13 2002;**55**(9):900-8.  
29  
30 14 44. Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised controlled trial in  
31  
32 15 patients with irritable bowel syndrome. *BMJ* 2008;**336**(7651):999-1003.  
33  
34 16 45. Roos E, Lohmander S. The knee injury and osteoarthritis outcome score (KOOS) - from joint injury to  
35  
36 17 osteoarthritis. *Health and Quality of Life Outcomes* 2003.  
37  
38 18 46. Klassbo M, Larsson E, Mannevik E. Hip disability and osteoarthritis outcome score. An extension of the  
39  
40 19 Western Ontario and McMaster Universities Osteoarthritis Index. *Scand J Rheumatol* 2003;**32**(1):46-  
41  
42 20 51.  
43  
44 21 47. Roos E, Roos H, Lohmander S, et al. Knee injury and osteoarthritis outcome score (KOOS) -  
45  
46 22 development of a self-administered outcome measure. *J Orthop Sports Phys Ther* 1998;**78**(2):88-96.  
47  
48 23 48. Roos EM, Toksvig-Larsen S. Knee injury and Osteoarthritis Outcome Score (KOOS) - validation and  
49  
50 24 comparison to the WOMAC in total knee replacement. *Health Qual Life Outcomes* 2003;**1**:17.  
51  
52 25 49. Roos EM, Roos HP, Ekdahl C, et al. Knee injury and Osteoarthritis Outcome Score (KOOS)--validation  
53  
54 26 of a Swedish version. *Scand J Med Sci Sports* 1998;**8**(6):439-48.  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 1 50. Nilsson AK, Lohmander LS, Klassbo M, et al. Hip disability and osteoarthritis outcome score  
5  
6 2 (HOOS)--validity and responsiveness in total hip replacement. *BMC Musculoskelet Disord*  
7  
8 3 2003;**4**:10.  
9  
10 4 51. McHorney CA, Ware JE, Raczek AE. The Mos 36-Item Short-Form Health Survey (Sf-36) .2.  
11  
12 5 Psychometric and Clinical-Tests of Validity in Measuring Physical and Mental-Health Constructs.  
13  
14 6 *Med Care* 1993;**31**(3):247-63.  
15  
16 7 52. McHorney CA, Ware JE, Lu JFR, et al. The Mos 36-Item Short-Form Health Survey (Sf-36) .3. Tests of  
17  
18 8 Data Quality, Scaling Assumptions, and Reliability across Diverse Patient Groups. *Med Care*  
19  
20 9 1994;**32**(1):40-66.  
21  
22 10 53. Ware JE, Sherbourne CD. The Mos 36-Item Short-Form Health Survey (Sf-36) .1. Conceptual-  
23  
24 11 Framework and Item Selection. *Med Care* 1992;**30**(6):473-83.  
25  
26 12 54. Bandura A. Self-Efficacy - toward a Unifying Theory of Behavioral Change. *Psychol Rev*  
27  
28 13 1977;**84**(2):191-215.  
29  
30 14 55. Lorig K, Chastain RL, Ung E, et al. Development and evaluation of a scale to measure perceived self-  
31  
32 15 efficacy in people with arthritis. *Arthritis Rheum* 1989;**32**(1):37-44.  
33  
34 16 56. Skou ST, Odgaard A, Rasmussen JO, et al. Group education and exercise is feasible in knee and hip  
35  
36 17 osteoarthritis. *Dan Med J* 2012;**59**(12):A4554.  
37  
38 18 57. Brady TJ. Measures of self-efficacy: Arthritis Self-Efficacy Scale (ASES), Arthritis Self-Efficacy Scale-  
39  
40 19 8 Item (ASES-8), Children's Arthritis Self-Efficacy Scale (CASE), Chronic Disease Self-Efficacy  
41  
42 20 Scale (CDSSES), Parent's Arthritis Self-Efficacy Scale (PASE), and Rheumatoid Arthritis Self-  
43  
44 21 Efficacy Scale (RASE). *Arthritis Care Res (Hoboken)* 2011;**63 Suppl 11**:S473-85.  
45  
46 22 58. Tubach F, Ravaud P, Baron G, et al. Evaluation of clinically relevant states in patient reported outcomes  
47  
48 23 in knee and hip osteoarthritis: the patient acceptable symptom state. *Ann Rheum Dis* 2005;**64**(1):34-  
49  
50 24 7.  
51  
52 25 59. Lesage FX, Berjot S. Validity of occupational stress assessment using a visual analogue scale. *Occup*  
53  
54 26 *Med (Lond)* 2011;**61**(6):434-6.  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 1 60. Astrand PO, Ryhming I. A nomogram for calculation of aerobic capacity (physical fitness) from pulse  
5  
6 2 rate during sub-maximal work. *J Appl Physiol* 1954;**7**(2):218-21.  
7  
8 3 61. Thorborg K, Bandholm T, Holmich P. Hip- and knee-strength assessments using a hand-held  
9  
10 4 dynamometer with external belt-fixation are inter-tester reliable. *Knee Surg Sports Traumatol*  
11  
12 5 *Arthrosc* 2013;**21**(3):550-5.  
13  
14 6 62. Ageberg E, Bennell KL, Hunt MA, et al. Validity and inter-rater reliability of medio-lateral knee motion  
15  
16 7 observed during a single-limb mini squat. *BMC Musculoskelet Disord* 2010;**11**.  
17  
18 8 63. Bremander AB, Dahl LL, Roos EM. Validity and reliability of functional performance tests in  
19  
20 9 meniscectomized patients with or without knee osteoarthritis. *Scand J Med Sci Sports*  
21  
22 10 2007;**17**(2):120-7.  
23  
24 11 64. Thorlund JB, Aagaard P, Roos EM. Thigh muscle strength, functional capacity, and self-reported  
25  
26 12 function in patients at high risk of knee osteoarthritis compared with controls. *Arthritis Care Res*  
27  
28 13 (Hoboken) 2010;**62**(9):1244-51.  
29  
30 14 65. Dobson F, Hinman RS, Hall M, et al. Measurement properties of performance-based measures to assess  
31  
32 15 physical function in hip and knee osteoarthritis: a systematic review. *Osteoarthritis Cartilage*  
33  
34 16 2012;**20**(12):1548-62.  
35  
36 17 66. Dobson F, Hinman RS, Roos EM, et al. OARSI recommended performance-based tests to assess physical  
37  
38 18 function in people diagnosed with hip or knee osteoarthritis. *Osteoarthritis Cartilage* 2013.  
39  
40 19 67. Wright AA, Cook CE, Baxter GD, et al. A comparison of 3 methodological approaches to defining major  
41  
42 20 clinically important improvement of 4 performance measures in patients with hip osteoarthritis. *J*  
43  
44 21 *Orthop Sports Phys Ther* 2011;**41**(5):319-27.  
45  
46 22 68. Gill S, McBurney H. Reliability of performance-based measures in people awaiting joint replacement  
47  
48 23 surgery of the hip or knee. *Physiother Res Int* 2008;**13**(3):141-52.  
49  
50 24 69. Tsai CY, Wang MC, Liao WT, et al. Hospital outpatient perceptions of the physical environment of  
51  
52 25 waiting areas: the role of patient characteristics on atmospherics in one academic medical center.  
53  
54 26 *BMC Health Serv Res* 2007;**7**.

- 1  
2  
3  
4 1 70. Jarvinen TLN, Sihvonen R, Bhandari M, et al. Blinded interpretation of study results can feasibly and  
5  
6 2 effectively diminish interpretation bias. *J Clin Epidemiol* 2014;**67**(7):769-72.  
7  
8 3 71. Davis BE. Rooftop Hospital Gardens for Physical Therapy: A Post-Occupancy Evaluation. *Health*  
9  
10 4 *Environments Research & Design Journal (HERD)* 2011;**4**(3):14-43.  
11  
12 5 72. Hrobjartsson A, Gotzsche PC. Placebo treatment versus no treatment. *Cochrane database of systematic*  
13  
14 6 *reviews* 2003(1):CD003974.  
15  
16 7 73. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? Update of a systematic review with 52 new  
17  
18 8 randomized trials comparing placebo with no treatment. *J Intern Med* 2004;**256**(2):91-100.  
19  
20 9 74. Thompson WG. Placebos: a review of the placebo response. *The American journal of gastroenterology*  
21  
22 10 2000;**95**(7):1637-43.  
23  
24 11 75. Di Blasi Z, Kleijnen J. Context effects. Powerful therapies or methodological bias? *Eval Health Prof*  
25  
26 12 2003;**26**(2):166-79.  
27  
28 13 76. Lang EV, Hatsiopoulou O, Koch T, et al. Can words hurt? Patient-provider interactions during invasive  
29  
30 14 procedures. *Pain* 2005;**114**(1-2):303-09.  
31  
32 15 77. Benedetti F, Amanzio M. The placebo response: how words and rituals change the patient's brain. *Patient*  
33  
34 16 *Educ Couns* 2011;**84**(3):413-9.  
35  
36 17 78. Bensing JM, Verheul W. The silent healer: the role of communication in placebo effects. *Patient Educ*  
37  
38 18 *Couns* 2010;**80**(3):293-9.  
39  
40 19 79. Essers G, Kramer A, Andriess B, et al. Context factors in general practitioner - patient encounters and  
41  
42 20 their impact on assessing communication skills - an exploratory study. *BMC Fam Pract* 2013;**14**.  
43  
44 21 80. Griffin SJ, Kinmonth AL, Veltmn MWM, et al. Effect on health-related outcomes of interventions to  
45  
46 22 alter the interaction between patients and practitioners: A systematic review of trials. *Ann Fam Med*  
47  
48 23 2004;**2**(6):595-608.  
49  
50 24 81. Lonsdale C, Hall AM, Williams GC, et al. Communication style and exercise compliance in  
51  
52 25 physiotherapy (CONNECT): a cluster randomized controlled trial to test a theory-based intervention  
53  
54 26 to increase chronic low back pain patients' adherence to physiotherapists' recommendations: study  
55  
56 27 rationale, design, and methods. *BMC Musculoskelet Disord* 2012;**13**:104.  
57  
58  
59  
60

- 1  
2  
3  
4 1 82. Neumann M, Edelhauser F, Kreps GL, et al. Can patient-provider interaction increase the effectiveness  
5  
6 2 of medical treatment or even substitute it?--an exploration on why and how to study the specific  
7  
8 3 effect of the provider. Patient Educ Couns 2010;**80**(3):307-14.  
9  
10 4 83. Suarez-Almazor ME, Looney C, Liu Y, et al. A randomized controlled trial of acupuncture for  
11  
12 5 osteoarthritis of the knee: effects of patient-provider communication. Arthritis Care Res  
13  
14 6 2010;**62**(9):1229-36.  
15  
16 7 84. Teutsch C. Patient-doctor communication. Med Clin North Am 2003;**87**(5):1115-45.  
17  
18 8 85. Thomas K. General practice consultations\_is there any point in being positive? Br Med J  
19  
20 9 1987;**294**(may):1200-02.  
21  
22  
23 10  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Flow chart, overview of the recruitment flow in the CONEX trial.  
175x184mm (96 x 96 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	N/A
Funding	4	Sources and types of financial, material, and other support	27
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	28
	5b	Name and contact information for the trial sponsor	N/A
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	28
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	22

1  
2  
3 **Introduction**

4				
5	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant	5-7
6	rationale		studies (published and unpublished) examining benefits and harms for each intervention	
7				
8		6b	Explanation for choice of comparators	8,12,23
9				
10	Objectives	7	Specific objectives or hypotheses	6,7
11				
12	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),	7
13			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	
14				

15  
16 **Methods: Participants, interventions, and outcomes**

17				
18	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will	N/A
19			be collected. Reference to where list of study sites can be obtained	
20				
21	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	7-8
22			individuals who will perform the interventions (eg, surgeons, psychotherapists)	
23				
24	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be	8-12
25			administered	
26				
27		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose	N/A
28			change in response to harms, participant request, or improving/worsening disease)	
29				
30		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence	15-18
31			(eg, drug tablet return, laboratory tests)	
32				
33		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N/A
34				
35	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	12-18
36			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,	
37			median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen	
38			efficacy and harm outcomes is strongly recommended	
39				
40	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for	Fig.1.
41			participants. A schematic diagram is highly recommended (see Figure)	
42				
43				
44				
45				



1				
2				
3	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	20
4				
5				
6	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	8
7				
8	<b>Methods: Assignment of interventions (for controlled trials)</b>			
9				
10	Allocation:			
11				
12	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	19
13				
14				
15				
16				
17				
18	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	19
19				
20				
21				
22	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	19
23				
24				
25	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	19-20
26				
27				
28		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	19-20
29				
30				
31				
32	<b>Methods: Data collection, management, and analysis</b>			
33				
34	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	12-20
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	15
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				

1				
2				
3	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	N/A
4				
5				
6				
7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	20-22
8				
9				
10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	N/A
11				
12		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	22
13				
14				
15				
16	<b>Methods: Monitoring</b>			
17				
18	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	22,28
19				
20				
21				
22				
23		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
24				
25				
26	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	18-19
27				
28				
29	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N/A
30				
31				
32				
33	<b>Ethics and dissemination</b>			
34				
35	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	7,25
36				
37				
38	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	N/A
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				

1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	N/A
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
7				
8				
9	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	N/A
10				
11				
12	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	28
13				
14				
15	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	N/A
16				
17				
18	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
19				
20				
21	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	N/A
22				
23				
24				
25				
26		31b	Authorship eligibility guidelines and any intended use of professional writers	N/A
27				
28		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N/A
29				
30	<b>Appendices</b>			
31				
32	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	N/A
33				
34				
35	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A
36				
37				

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

# BMJ Open

## Exploring the Effect of Space and Place on Response to Exercise Therapy for Knee and Hip Pain; a protocol for a double-blind randomised controlled clinical trial. The CONEX trial

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2015-007701.R1
Article Type:	Protocol
Date Submitted by the Author:	19-Feb-2015
Complete List of Authors:	Sandal, Louise; University of Southern Denmark, Institute of Sport Science and Clinical Biomechanics Thorlund, Jonas; University of Southern Denmark, Institute of Sports Science and Clinical Biomechanics Ulrich, Roger; Chalmers University of Technology, Dieppe, Paul; University of Exeter Medical School, Institute of Health Research Roos, Ewa; University of Southern Denmark, Institute of Sports Science and Clinical Biomechanics
<b>Primary Subject Heading</b>:	Sports and exercise medicine
Secondary Subject Heading:	Rehabilitation medicine, Patient-centred medicine, Rheumatology
Keywords:	SPORTS MEDICINE, Hip < ORTHOPAEDIC & TRAUMA SURGERY, Knee < ORTHOPAEDIC & TRAUMA SURGERY, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY

SCHOLARONE™  
Manuscripts

1 Exploring the Effect of Space and Place on Response to Exercise Therapy  
2 for Knee and Hip Pain; a protocol for a double-blind randomised  
3 controlled clinical trial. The CONEX trial  
4

5 **Author information**

6 Louise Fleng Sandal, Department of Sports Science and Clinical Biomechanics, University of Southern  
7 Denmark, Odense, Denmark, [lsandal@health.sdu.dk](mailto:lsandal@health.sdu.dk).

8 Jonas Bloch Thorlund, Department of Sports Science and Clinical Biomechanics, University of Southern  
9 Denmark, Odense, Denmark, [jthorlund@health.sdu.dk](mailto:jthorlund@health.sdu.dk)

10 Roger S. Ulrich, Chalmers University of Technology, Gothenburg, Sweden, [roger.s.ulrich@gmail.com](mailto:roger.s.ulrich@gmail.com)

11 Paul A. Dieppe, University of Exeter, Medical School, Exeter, UK, [p.dieppe@exeter.ac.uk](mailto:p.dieppe@exeter.ac.uk)

12 Ewa M. Roos, Department of Sports Science and Clinical Biomechanics, University of Southern Denmark,  
13 Odense, Denmark, [eroos@health.sdu.dk](mailto:eroos@health.sdu.dk)

14  
15 **Corresponding author:**

16 Louise Fleng Sandal, Ph.D. Student

17 Research Unit for Musculoskeletal Function and Physiotherapy

18 Department for Sports Science and Clinical Biomechanics

19 University of Southern Denmark

20 Campusvej 55

21 5230 Odense M

22 Denmark

23 Phone: + 45 65 50 43 84

24 Email: [lsandal@health.sdu.dk](mailto:lsandal@health.sdu.dk)

25

- 1 **Keywords:** Joint pain, context effect, exercise, physical environment.
- 2 Word count: 38434

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 ABSTRACT

### 2 Introduction

3 '*Context effects*' are described as effects of a given treatment, not directly caused by the treatment  
4 itself, but rather caused by the context in which treatment is delivered. Exercise is a recommended  
5 core treatment in clinical guidelines for musculoskeletal disorders. Although overall moderately  
6 effective, variation is seen in size of response to exercise across RCT studies. Part of this variation  
7 may be related to the fact, that exercise interventions are performed in different physical  
8 environments, which may affect participants differently. The study aims to investigate the effect of  
9 exercising in a contextually enhanced physical environment for 8 weeks for people with knee or hip  
10 pain.

11

### 12 Methods and analysis

13 The study is a double-blind randomised controlled trial. Eligible participants are 35 years or older  
14 with persisting knee and/or hip pain for 3 months. Participants are randomised to one of three  
15 groups; 1) exercise in contextually enhanced environment 2) exercise in standard environment 3)  
16 waiting list. The contextually enhanced environment is located in a newly built facility, has large  
17 windows providing abundant daylight, overlooking a recreational park. The standard environment is  
18 in a basement, has artificial lighting and is marked of use, i.e. resembling many clinical  
19 environments. Primary outcome is participant's global perceived effect rated on a 7-point Likert  
20 scale after 8 weeks exercise. Patient-reported and objective secondary outcomes are included.

21

### 22 Ethics and dissemination

1 The Regional Scientific Ethical Committee for Southern Denmark has approved the study. Study  
2 findings will be disseminated in peer-reviewed publications and presented at national and  
3 international conferences.

4 **Trial registration:** NCT02043613

#### 6 **Strengths and limitations of the study**

7 The randomised controlled trial aims to investigate the effect of the physical environment on the  
8 effect of exercise therapy and focuses on the significance of the context in which treatment is  
9 delivered.

10 The physical environment is a single component of the multifactorial concept of contextual effect  
11 and isolating only one component may be difficult as interaction between several components may  
12 occur.

13



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 INTRODUCTION

2 The physical environment affects the persons in it and may potentially be of significance for health  
3 and treatment effects. Studies on the role of physical environments conducted in hospital settings  
4 have reported that factors such as noise, daylight deprivation and light intensity may increase stress  
5 and pain level, reduce patient satisfaction and affect length of hospital stay<sup>1-5</sup>. Many rehabilitation  
6 and hospital exercise facilities are today located in large rooms in basements or other windowless  
7 rooms with poor acoustics, not designed for optimal exercise therapy delivery. These physical  
8 environments may affect patients negatively and potentially result in a poorer result from the  
9 exercise or rehabilitation, if patients are feeling unwelcomed or are not motivated to comply with  
10 the exercise in the given environment. Theoretically, enhanced physical environments may create  
11 positive atmosphere, enhance communication during exercise and potentially improve exercise  
12 performance, compliance and perceived wellbeing. Exercise is recommended as a life-long  
13 treatment for chronic diseases such as cardiovascular diseases, diabetes and musculoskeletal  
14 disorders, including hip and knee osteoarthritis (OA) and joint pain. Despite high-level evidence  
15 that exercise provides on average moderate pain relief and functional improvement in patients with  
16 osteoarthritis, large variation in effect is observed across studies and treatment effects may vary  
17 from small to large<sup>6, 7</sup>. In addition to differences in characteristics of the exercise programs studied,  
18 this may also relate to the fact that exercise interventions have been performed in different physical  
19 environments and that these environments may influence patients differently<sup>8</sup>. It is plausible, but  
20 currently unknown, whether the physical environment can be modified in ways, that enhances the  
21 effect of exercise therapy. To our knowledge, this is the first trial to actively investigate if  
22 modification of the physical environment can be used in a positive way to enhance the effect from  
23 exercise therapy.

24

1 This study applies the term ‘context effect’ as a framework for elucidating how treatment effect is  
2 potentially caused by a complexity of factors in addition to the actual treatment effect. Context  
3 effects are defined as the effects of a given treatment, not directly caused by the treatment itself, but  
4 rather caused by the context or environment in which the treatment is given<sup>8-11</sup>. Context effects may  
5 be considered as a parallel to placebo effects, which has been one of the most debated topics in  
6 modern medicine<sup>12-15</sup>. Several authors have objected to the term placebo, as they argue, that the  
7 definition is self-contradictory and inadequate<sup>9, 16-19</sup>. Placebo is in its classical term defined as  
8 giving an inert substance or treatment<sup>10, 18</sup>. However, if placebos are inert, they cannot have an  
9 effect, and if they have an effect, they cannot be inert<sup>9, 10, 16, 18</sup>. Other terms have been suggested,  
10 such as; non-specific effect, non-characteristic effect, incidental effects, meaning response, placebo  
11 components and context effects, as applied in this study<sup>9, 20-24</sup>. A clear distinction should be made  
12 between placebo effects and context effects. Placebo is associated with giving pills, injections or  
13 having surgery and often entails a form of deliberate deception, whereas context effects rather  
14 classify factors creating or enhancing a treatment effect<sup>8-11</sup>. Factors contributing to context effects  
15 can be divided into different categories, such as; characteristics of the patient and the practitioner,  
16 type of treatment, nature of disease and the physical environment<sup>8, 11</sup>. This study will focus on the  
17 physical environment where exercise therapy is delivered, as it can be modified in a standardised  
18 and reproducible way to potentially enhance adherence and enhance the positive effects of exercise  
19 therapy.

20  
21 The study aim is to investigate the effect of exercising in a contextually enhanced physical  
22 environment for 8 weeks for people with knee or hip pain. We hypothesize that, participants  
23 exercising according to a standardised program in a contextually enhanced physical environment  
24 will report greater improvement from exercise compared to participants following the same

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 exercising program in a standard physical environment as measured by patients' Global Perceived  
2 Effect (GPE). Further, we expect that the two exercise groups will be superior to a passive waiting  
3 list.

## 5 **METHODS AND ANALYSIS**

### 6 **Study design**

7 This study is designed as a 3-armed randomised controlled clinical trial. Participants are randomised  
8 to three intervention groups; exercise in a context enhanced physical environment (EX+ROOM),  
9 exercise in a standard physical environment (EX) or waiting list (WL). Participants, investigators  
10 and exercise instructors are blinded to treatment allocation. Primary endpoint is patient's global  
11 perceived effect assessed after 8 weeks exercise on a 7-point Likert scale. The Regional Scientific  
12 Ethical Committee for Southern Denmark has approved the study (study ID: S-20130130). It is  
13 consistent with the Helsinki Declaration and registered with [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (ID:  
14 NCT02043613). Results from this study will be reported according to the CONSORT statement<sup>25</sup>.

### 16 **Participants**

17 Eligible participants are 35 years or older, self-reporting persisting knee and/or hip pain within the  
18 last 3 months and are willing and able to attend exercise therapy twice weekly at the University of  
19 Southern Denmark, Odense M. Exclusion criteria are: 1) Co-morbidities or contraindication  
20 prohibiting participation in exercise therapy; 2) Inability to answer questionnaires or to speak, read  
21 or understand Danish; 3) Already participating in exercise therapy, defined as an exercise program  
22 supervised by a physiotherapist, or systematic training with duration of 6 weeks or more started  
23 within 3 months to inclusion, aimed specifically at relieving knee or hip joint problems; 4) Having  
24 had surgery to the hip/knee within the last 3 months or waiting for joint surgery in the coming 6

1 months. Participants are recruited via different pathways; posters and informational leaflets at  
2 general practitioners offices, the orthopaedic department at Odense University Hospital or  
3 participant initiated contact through posters and articles in local newspapers, social media and word  
4 of mouth (figure 1). Participants are screened via telephone and if eligible, they are invited to a  
5 baseline visit and written information is sent to the participants. At the baseline visit the primary  
6 investigator gives oral information regarding the study and the participant signs the consent form if  
7 willing to participate. Baseline testing is performed directly hereafter.

8  
9 **Insert Figure 1 around here**

### 10 11 **Intervention**

12 Participants are randomly assigned to one of three groups.

#### 13 14 *Group EX+ROOM: exercise in contextually enhanced physical environment*

15 This exercise room is placed on the second floor in a newly build facility. It has a view to a newly  
16 reconstructed outdoor sport and recreational park. It has not prior been used in studies investigating  
17 exercise as a treatment option.

#### 18 19 *Group EX: exercise in a standard physical environment*

20 This group will exercise in a room, which has been used in other exercise studies. The room is  
21 marked by years of use. It is placed in the basement and accessed through a series of staircases and  
22 hall-ways through the basement. This facility resembles many existing exercise facilities at  
23 hospitals and rehabilitation clinics and is considered a standard exercise environment.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### 1 *Contextual factors*

2 The physical environments are described and classified by a variety of contextual factors (**table 1**).

3

4 Acoustic properties such as speech interpretability, reverberation and background noise are

5 measured by use of standard acoustic methods<sup>26</sup>. Better acoustic properties, such as shorter

6 reverberation time and higher speech interpretability, may reduce stress and improve

7 communication. In hospital environments high noise levels are associated with worse patient

8 outcomes such as psychological stress and satisfaction with care<sup>27</sup>. Background noise (dB(A)) is

9 measured in empty rooms. Reverberation is measured as T20, the time interval for a 20 dB decay

10 within a room. Reverberation is a measure of how long it takes for sound to decay in a room and a

11 long reverberation time affects speech comprehension negatively<sup>26</sup>. Reverberation and speech

12 interpretability are descriptive of how well speech is perceived in a room. Speech interpretability is

13 measured as speech clarity and transmission. Speech clarity is measured as a Clarity Index within

14 the initial 50ms (C50), it compares early sound reflection with later sound reflection. Early sound

15 reflections are positive for speech interpretability and later sound reflection will be perceived as

16 noise. A high C50 indicates good speech interpretability. Speech Transmission index (STI) is a

17 measure of sound quality in transmission from sound source to receiver. Reverberation and speech

18 interpretability are derived from tape recordings of loud clear noises emitted in the exercise rooms.

19 Acoustic measures are obtained from two positions in the room with small, medium and large

20 distance to the sound source. Light intensity is assessed using an adapted method from Walch et al,

21 2005. Light intensity is measured using a LUX meter (Amprobe, LM-100, light meter, Everett, WA,

22 USA) on two representative positions in the exercise rooms and additionally directly at windows, if

23 present in the room. Three consecutive measures are obtained from each position and averaged.

24 Light measurements are taken as close to the exercise time as possible. Daylight and brighter rooms

1 are associated with lower pain perception and lower postoperative analgesic intake in hospital  
 2 environments<sup>28, 29</sup>. Air quality is described by CO<sub>2</sub> concentration, temperature and air humidity in  
 3 the exercise rooms during exercise. Air quality is assessed with an air quality data logger, set to  
 4 collect data on 30 sec. intervals (Trotec, BZ-30, data logger, Heinsberg, Germany). Furthermore,  
 5 carefully selected pictures of nature scenes are hung in the contextually enhanced physical  
 6 environment. Viewing nature pictures or visual stimuli of nature elements have been known to  
 7 reduce stress in office setting and influence recovery time and decrease pain in patients following  
 8 surgery<sup>1, 5, 30-33</sup>.

10 **Table 1:** Descriptive environmental factors

Dimension	Factor	Contextually enhanced physical environment	Standard physical environment
Indoor environment	Light		
	- Strength (Lux)	@	@
	- Source	Daylight + artificial light	Artificial light.
	- Window/no window	Windows, Floor to ceiling	No windows
Indoor environment	Air quality		
	- CO <sub>2</sub> (ppm)	@	@
	- Temperature (°C)	@	@
	- Humidity (%)	@	@
Indoor environment	Sound/noise		
	- Background noise (dB(A))	@	@
	- Speech clarity (C50, STI)	@	@
	- Reverberation (T20)	@	@
Décor	Wall decorations	Picture of nature scenes	No decorations

	View	View of nature and outdoor exercise environment	No view
--	------	--	---------

Table 1: Parameters assessed in the different physical environments @ = assessed/measured and will be reported. Ppm: parts per million, C50, clarity index with first 50 ms of sound, STI: speech interpretability index, T20: reverberation time for sound decay of 20 dB.

### *Exercise*

The exercise program for participants in the EX+ROOM and EX group is based on the standardised NEuroMuscular EXercise (NEMEX) program. It is described in detail elsewhere<sup>34</sup> and has previously been investigated for feasibility in patients with severe knee or hip OA<sup>34</sup>. The NEMEX program is based on biomechanical and neuromuscular principles, which aim to improve sensorimotor control and achieve functional stability<sup>34</sup>. The NEMEX program has previously been shown to be effective to relieve pain and improve function in populations with knee or hip pain such as anterior cruciate ligament injuries<sup>35-38</sup>, meniscectomized participants<sup>39, 40</sup> patients with hip or knee OA undergoing total joint arthroplasty<sup>34, 41</sup>. Exercise is performed as group exercise and all exercise sessions are supervised. All instructors will be certified in the NEMEX program. To ensure consistency between instructors, they will participate in a two-day course, Good Life with osteoarthritis in Denmark, focusing on lower-limb osteoarthritis management and neuromuscular exercise. After completing the course all instructors will go through the exercise program with the primary investigator to ensure consistency in instructing and supervising exercise as well as going through how volume, load and progression of exercise and pre- and post-exercise pain should be documented in participants' exercise dairies. The EX+ROOM and EX group will exercise on the same weekdays, twice a week for one hour duration. An instructor will first supervise the EX+ROOM group and then the EX group. Consequently, all of the instructors will have supervised the NEMEX program in both physical environments and for the same amount of time, i.e. if an



1 instructor supervises the EX+ROOM group then they supervise the EX group as well. This is done  
2 to ensure consistency in delivery instructions and supervision of exercise across study participants  
3 and to ensure that any effect that a given instructors may have on the exercise and participants  
4 should be similar between physical environments.

#### 6 *Group WL: waiting list/control group*

7 Participants randomised to waiting list are placed on a passive waiting list for a period of 8 weeks,  
8 and thereafter offered 8 weeks of structured resistance exercise. These participants act as an  
9 observational group and represent the natural course of disease in participants with knee and/or hip  
10 pain. After the 8 weeks when follow-up data for the current study has been collected, the  
11 participants are offered resistance exercise rather than neuromuscular exercise for logistic reasons,  
12 such as avoiding taking up place in the designated exercise rooms used in the study and  
13 consequently affecting the time to completion of the study.

#### 15 **Primary outcome**

16 Participants' Global Perceived Effect (GPE) assessed at 8 weeks will be the primary endpoint of the  
17 trial. Participants are asked to respond to the following question; "*Compared to before you entered*  
18 *the study, how are your knee/hip problems now?*" on a 7-point Likert scale. The GPE scale ranges  
19 from 'markedly worse' through 'no change' to 'markedly improved'. GPE is a reliable method for  
20 measuring the effect of clinical interventions<sup>42, 43</sup>. It has prior been used in studies investigating  
21 contextual effect of treatment<sup>44</sup>. The validity of GPE scales has been questioned. However, a study  
22 on the correlation between transition ratings and pre and post score of quality of life questionnaires  
23 showed a correlation of 0.8 between the change score of the questionnaire and the transition ratings



1 suggesting that transition scales, such as global perceived effects, are valid for detecting changes  
 2 and can be used in clinical trials as primary outcome measures<sup>43</sup>.

#### 4 Secondary outcomes

5 All outcomes and time points for data collection are listed in **table 2**.

7 **Table 2:** Summary of collected data and time points

Variable	Baseline	4 weeks	8 weeks
<b>Baseline data</b>			
Height (cm)	@	n.a.	@
Weight (kg)	@	n.a.	@
Age (yrs.)	@	n.a.	n.a.
Gender ( f/m)	@	n.a.	n.a.
Marital status	@	n.a.	n.a.
Educational level	@	n.a.	n.a.
Employment status	@	n.a.	n.a.
Alcohol consumption	@	n.a.	n.a.
Smoking	@	n.a.	n.a.
Physical activity level at work and leisure	@	n.a.	n.a.
<b>Primary outcome</b>			
Global Perceived Effect (7 point Likert scale).	n.a.	@	@
<b>Secondary outcomes</b>			
<b>Patient reported outcomes</b>			
Knee/Hip Injury and Osteoarthritis Outcome Score	@	@	@
Short-form 36 Health Survey	@	@	@

Modified Arthritis Self-Efficacy Scale	@	@	@
Patient Acceptable Symptom State (y/n)	n.a.	n.a.	@
Patient satisfaction (5 point Likert scales).	n.a.	n.a.	@
Stress (100 mm VAS)	@	n.a.	@
<b>Objective physical function tests</b>			
Aerobic capacity (ml O <sub>2</sub> /min/kg)	@	n.a.	@
Isometric strength hip abduction (Nm)	@	n.a.	@
Isometric strength knee extension (Nm)	@	n.a.	@
Single-limb mini squat	@	n.a.	@
Knee bends/30 sec. (no.)	@	n.a.	@
Chair stands/30 sec. (no.)	@	n.a.	@
Walking test, 40 m fast paced. (sec)	@	n.a.	@
One-leg hop of distance (cm)	@	n.a.	@

Table 2: Summary of primary and secondary outcomes and respective time collection points, @ = assessed/measured, n.a. = not assessed VAS: visual analogue scale.

#### *Patient reported outcomes*

Participants answer the Danish versions of the Knee injury and Osteoarthritis Outcome Score (KOOS) or The Hip disability and Osteoarthritis Outcome Score (HOOS) depending on either knee or hip problems being primary complaint. The KOOS and the HOOS are joint-specific questionnaires, developed to assess participants' opinion about their knee or hip problems<sup>45, 46</sup>. KOOS/HOOS consists of 5 subscales; pain, symptoms, activities of daily life function, sport and recreational function and joint related quality of life<sup>47</sup>. Each subscale consists of a set of items specific to the subscale and each item is assessed via a Likert scale with 5 possible answer options ranging from 0 (no problems) to 4 (extreme problems). The Likert score is transformed to a 0-100 scale with zero representing extreme knee problems and 100 representing no knee problems<sup>45</sup>.

1  
2  
3  
4 1 KOOS and HOOS have good psychometric properties for patient groups with knee injury, knee  
5  
6 2 replacement, hip dysfunction and hip replacement<sup>46-50</sup>.

7  
8  
9 3 The Medical Outcome Study 36-item short form general health survey (SF-36) is a generic patient-  
10  
11 4 reported health status measure<sup>51-53</sup>. It consists of 36 items organised under 8 subscales; 1) physical  
12  
13 5 functioning, 2) role limitations because of physical health, 3) bodily pain, 4) social functioning, 5)  
14  
15 6 general mental health, 6) role limitations because of emotional problems, 7) vitality, and 8) general  
16  
17 7 health perception<sup>53</sup>. Low scores indicate limitations in activities and a perception of poor health,  
18  
19 8 high score indicate no limitations and good health<sup>53</sup>. Validity and reliability of the SF-36 is  
20  
21 9 adequate and the questionnaire is widely used<sup>51, 52</sup>.

22  
23  
24 10 A modified measure of self-efficacy is included to evaluate patients' perception of functionality or  
25  
26 11 limitations to their functionality caused by their knee or hip problem. Self-efficacy is defined by  
27  
28 12 Bandura as "belief in one's capability to organise and execute the course of action required to  
29  
30 13 produce given attainments<sup>54</sup>. Self-efficacy is assessed with a modified version of the Arthritis Self-  
31  
32 14 Efficacy Scale (ASES)<sup>55</sup> previously used in a similar patient group<sup>56</sup>. The modified version of  
33  
34 15 ASES consists of 11 single items from the two subscales pain and other symptoms. Participants rate  
35  
36 16 their ability to cope with pain and symptoms related to their joint problem, on a 10-100 scale, with  
37  
38 17 10 indicating very uncertain and 100 indicating very certain with 10 point increments<sup>57</sup>.

39  
40  
41 18 A series of single item questions are included. Patient Acceptable Symptom State is assessed by  
42  
43 19 asked a single yes/no question; "Considering your knee function, do you feel that your current state  
44  
45 20 as satisfactory? With knee function you should *take into account all the activities you have during*  
46  
47 21 *your daily life, your level of pain and other symptoms and your quality of life*"<sup>58</sup>. If participants rate  
48  
49 22 their current symptom state as unacceptable, a follow-up question is asked as to if they consider the  
50  
51 23 treatment to have failed. Further, participants are asked to answer five global perceived effects  
52  
53 24 questions specific for each of the five subscales of either KOOS or HOOS, rating either  
54  
55  
56  
57  
58  
59  
60

1 improvement or deterioration and finally an indication of whether these changes are perceived as  
2 important or unimportant by the participants. These single items are included in order to assess  
3 minimal clinical important changes for the five subscales of the KOOS and HOOS. Stress is  
4 estimated as 'general stress level' measured on a 100 mm visual analogue scale ranging from no  
5 stress to stress as severe as could be<sup>59</sup>.

6 Patient reported outcomes are collected using an online survey. At baseline and 8 weeks follow-up  
7 participants answer the survey on a computer in the examination room without the investigator  
8 present. At 4-week follow-up an email is sent to participants, who answer at home. To ensure high  
9 data completion an email reminder is sent, if no reply is received within 3-5 days. Further,  
10 participants are called by phone if there is no reply to the reminder e-mail.

### 11 12 *Functional performance*

13 Patients' aerobic capacity is estimated during a submaximal work rate bicycle test<sup>60</sup>. Patients pedal  
14 until reaching a steady state, with a stable pulse rate ranging between 120 to 170 beats per minute,  
15 normally within 6-7 minutes<sup>60</sup>. Participants' aerobic capacity is estimated from work rate and  
16 stable pulse rate by use of Åstrand's Nomogram<sup>60</sup>.

17 Maximal isometric knee extension and hip abduction strength will be tested using dynamometry  
18 (JTECH medical, Commander Echo, Salt Lake City, Utah, USA). A suction cup is mounted on a  
19 door behind the examination couch. A strain gauge, measuring pull in newton, is placed in between  
20 the suction cup and a fixation belt strapped around the participant's ankle above the lateral malleoli.

21 For knee extension, participants sit on an examination couch with a hip angle of 90° and a knee  
22 angle of 90°. Participants are asked to press against their foot the belt in a forward motion. The  
23 distance from the knee joint axis to the middle of the fixation belt is measured. Consequently,  
24 isometric muscle strength is measured as torque. For hip abduction, participants lie on the couch

1 with their leg straight and are asked to press their lateral malleoli against the belt. The distance from  
2 the trochanter major on the femoral bone to the middle of the fixation belt is measured. One practice  
3 trial is allowed and thereafter three maximal contractions are performed separated by a 60 sec.  
4 pause. Isometric muscle strength is normalised to body weight to increase comparability. The  
5 methods for assessing isometric muscle strength have been adapted from Thorborg et al. who  
6 reported good inter-tester reliability with an interclass correlation coefficient ranging from 0.76 –  
7 0.95 and standard error of measurement between 5.0% to 10.4% for hip and knee strength  
8 assessments<sup>61</sup>.

9 Physical function is assessed by 5 performance tests; 1) single limb mini squats<sup>62</sup>, 2) number of  
10 knee bendings on one leg during 30 sec standing<sup>63, 64</sup>, 3) number of chair stands during 30 sec<sup>65, 66</sup>,  
11 4) 40 m fast-paced walking test<sup>65</sup> and 5) one leg hop for distance<sup>63</sup>. All performance tests have been  
12 found valid to assess lower extremity function in different patient groups with knee or hip  
13 problems<sup>63, 66-68</sup>. As large variation regarding age and function within participants of this trial is  
14 expected, and therefore a test battery with a wide range of difficulty of the performance tests is  
15 chosen to ensure that all participants would be challenged. A floor effect may be evident in the one  
16 leg hop for distance test as some participants may not be able to hop at all. No ceiling effects are  
17 expected for any of the functional performance measures.

### 19 **Explanatory outcomes and nested qualitative study**

20 To investigate how the physical environment and other potential context factors, such as participant  
21 and practitioner interaction and behaviour, may interact and mediate the treatment effects,  
22 explanatory outcomes are included. Explanatory outcomes have been selected to explain the process  
23 by which context effects work and possibly elucidate which elements within the physical  
24 environment that enhance treatment effects and how these elements affect the patients and

1 practitioners. A qualitative study will be embedded within the randomised controlled trial design.  
2 The aim of the qualitative study is to investigate, how the participants experience the two different  
3 physical environments. Observation is performed in both rooms during exercise sessions to describe  
4 and identify behaviour of practitioners and participants specific to the different physical  
5 environments. Focus group interviews will be conducted with participants to investigate their  
6 experiences with the exercise environments and to invite participants to articulate and elaborate on  
7 their thoughts on how the physical environment has affected them. Three focus group interviews  
8 will be conducted with a total of 10 to 20 participants from the contextually enhanced physical  
9 environment and 3 focus group interviews with similar number of participants from the standard  
10 physical environment, i.e. 6 focus groups in total. Participants invited to the focus groups will be  
11 those randomized to exercise in the RCT design (group EX+ROOM and group EX). The interviews  
12 will be transcribed and analysed using thematic coding comparing within and across the different  
13 physical environments. Additionally, in-depth individual interviews will be performed with 6  
14 participants. To ensure the blinding of participants throughout the study all interviews will be  
15 conducted after the intervention and after follow-up testing has been completed.

16 Additionally, a patient reported outcome 'participant satisfaction' is reported as participants'  
17 satisfaction with the exercise intervention in itself as well as satisfaction with specific contextual  
18 factors within the physical environment. Eleven single items scoring the different factors of the  
19 physical environment such as lighting, cleanliness, access, decoration etc. are administered to  
20 participants in intervention groups EX+ROOM and EX. The items are adapted from Tsai et al.<sup>69</sup>.  
21 Satisfaction is scored on a 5-point Likert scale ranging from 1 to 5 (1=strongly dissatisfied,  
22 2=dissatisfied, 3=fair, 4=satisfied, and 5=strongly satisfied).

## 23 24 **Compliance and adverse events**

1 In the two exercise groups, compliance is considered good at 75% or if 12 of 16 possible exercise  
2 sessions are attended. Participants in the WL group are asked at 8 weeks follow-up, whether they  
3 have started any exercise courses with the last 8 weeks. If answering yes, they are asked to describe  
4 the change. This is done in order to account for compliance to the waiting list design. Self-reported  
5 adverse events occurring in-between exercise sessions are recorded at 4 and 8 weeks in the online  
6 survey. Adverse events are defined as any events that the participants found restricting them  
7 physically, mentally or socially. Participants also indicate whether of they have been in contact with  
8 either their general practitioner or the hospital in relation to their adverse event. Any adverse events  
9 occurring during the exercise sessions are recorded by the supervising instructors.

### 11 **Randomisation**

12 Randomisation is performed immediately after baseline assessment and is administered by a  
13 research coordinator, not otherwise involved in the study. Patients are consecutively assigned and  
14 given a numbered, sealed, opaque envelope entailing treatment allocation. The randomisation  
15 sequence is computer-generated and prepared by a statistician with no clinical involvement in  
16 conducting the trial. To avoid imbalances in treatment allocation among people with knee and hip  
17 pain, two block randomisation lists were computer-generated (with a 2:2:1 allocation). The block  
18 size is kept secret to maintain blinding; each block consisted of either 5 or 10 patients. The  
19 randomisation lists and envelopes are kept in a secure location at the university.

### 21 **Blinding procedure**

22 Participants are blinded to the study aim in order to avoid excess focus on the physical environment,  
23 which potentially could exaggerate context effects from the physical environment. Participants are  
24 therefore informed that they are participating in a study evaluating the effects from exercise



1 compared to being on a waiting list and are not made aware that the true aim of the study is to  
2 investigate the possible additional effect from an enhanced physical environment on exercise. The  
3 instructors supervising the exercise sessions are neither informed about the true aim of the study.  
4 However, they are aware that exercise sessions are performed in different rooms as they supervise  
5 sessions in both rooms. The instructors have been informed that the different exercise rooms are  
6 used for practical and logistic reasons. The primary investigator conducting baseline and follow-up  
7 testing is also blinded to treatment allocation and participants are instructed to not to speak about  
8 the intervention with the investigator, thereby keeping blinding intact.

#### 10 **Sample size estimation and power considerations**

11 This study is designed as a superiority trial with three groups (EX+ROOM, EX and WL). Since this  
12 is the first study to investigate the additional effect of an enhanced physical environment on the  
13 effect of exercise therapy as treatment for knee or hip pain, there are no previous data to base our  
14 sample size estimation on. Thus the power calculation is based on factors such as feasibility, i.e.  
15 how many participants will be realistic to include with the recruitment period and pragmatic issues  
16 such as availability and capacity of the different exercise rooms. Taking these aspects into  
17 consideration 100 participants will be included into the trial. To be able to account for the natural  
18 disease progression or regression towards the mean the waiting list (WL) is included in the design.  
19 A randomisation with a 2:2:1 allocation is chosen and thus 40 participants are randomised to  
20 EX+ROOM and EX groups, respectively, and 20 participants are randomised to the WL group. We  
21 anticipate that individuals in the WL group will experience limited effect. With 40 subjects in each  
22 of the two exercise groups (EX+ROOM and EX), we are able to detect a difference of 0.75 on the  
23 GPE scale ranging from -3 to 3 with a standard deviation of 1.2, a p-value of 0.05 and a power of  
24 80%.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1

## 2 **Statistical evaluation**

3 All three intervention groups (EX+ROOM, EX and WL) will be examined for comparability at  
4 baseline with respect to demographic factors using ANalysis Of VAriance (ANOVA) and Chi-  
5 squared test as appropriate.

6 The primary analysis on the GPE data will be conducted with a Student's unpaired t-test comparing  
7 the EX+ROOM intervention group with EX intervention group at the 8-week follow-up. The  
8 Bonnet-Price median test will be conducted if assumption of normality in the GPE data is not  
9 supported. The WL intervention group is considered a reference group describing the natural  
10 progression of disease for the included study population and is not included in the primary analysis.  
11 However, to check the general assumption, that exercise is more effective than no intervention, an  
12 unpaired t-test is conducted to compare the exercise groups with the waiting list.

13 The secondary outcomes, the KOOS/HOOS, SF-36, ASES and physical function outcomes are  
14 analysed as repeated measures (i.e. change from baseline over 4 and 8 weeks follow-up for patient  
15 reported outcomes and baseline to 8 week follow-up for physical function tests) applying a mixed  
16 linear effects model with 'participant' as random effect and sex, age and joint as fixed effects. As  
17 for the primary outcome, only the EX+ROOM and EX groups are compared. Additionally, to test  
18 an *a priori* hypothesis of a graded relationship between groups EX+ROOM > EX > WL a linear test  
19 for trend will be conducted as an explanatory analysis on all outcomes. Here, a  $\chi^2$  test for trend is  
20 applied for dichotomous outcomes and a linear test for trend is applied for continuous outcomes.  
21 Pairwise comparison of groups will be conducted if the trend test was significant, to describe the  
22 association between group and outcome, i.e. EX+ROOM vs EX and EX vs WL. For dichotomised  
23 outcomes a  $\chi^2$  test is applied, and for continuous ANOVA is applied.

1 Intention-to-treat analysis is performed and last observation is carried forward for missing data at  
2 follow-up for the secondary outcomes. The primary outcome is a transition score, which is not  
3 assessed as baseline. For any participants lost to follow-up GPE data will be missing. Further, a per-  
4 protocol analysis is conducted including only those with good compliance with the exercise  
5 intervention (participated in at least 12 of 16 sessions) in the EX+ROOM and EX groups,  
6 respectively.

7 A detailed statistical analysis plan will be drafted and approved by all authors before being  
8 made publicly available prior to breaking randomisation code and conducting data analysis. To  
9 further minimise the risk for bias introduced during analysis and interpretation, data analysis will be  
10 performed by a third party not otherwise related to the study. Intervention groups will be allocated  
11 with arbitrary names. Interpretation will be performed by the primary investigator in collaboration  
12 with the research team prior to revealing treatment allocation, thereby interpreting the results  
13 blindly<sup>70</sup>. Consequently, two interpretation scenarios will be drafted on the basis of the primary  
14 outcome data, i.e. comparing treatment A with treatment B. One assuming that group A will be the  
15 EX+ROOM group and another assuming that A will be the EX group.

## 17 **ETHICS AND DISSEMINATION**

18 The findings of this study will be disseminated through peer-reviewed publications and through  
19 international conference presentations.

20 The primary ethical concern in this study is that the true aim of the study is withheld from  
21 participants. Withholding the aim disables participants to consider the implications of the research  
22 and to assess whether or not they want to contribute to investigating this aim. However, blinding the  
23 true aim is imperative to the study design as an effect from the physical environment may be over-  
24 or underestimated, if participants are explicitly made aware of the actual aim of the study.

1  
2  
3  
4 1 Participants are therefore told that the study is designed to investigate the effect of neuromuscular  
5  
6 2 exercise as an early treatment strategy for musculoskeletal pain. Similarly the supervising  
7  
8 3 instructors are also blinded to the true aim of the study. Instructors are aware that the exercise is  
9  
10 4 performed in different environments, but are told this due to logistic reasons. The ethics committee  
11  
12 5 has been explicitly made aware that study participants and instructors are not made aware of the  
13  
14 6 true study aim and despite this sanctioned the study without any reservations or conditions.  
15  
16  
17  
18  
19  
20

## 21 **DISCUSSION**

22 9 Context effects may constitute an important part of the effects of exercise therapy. Investigating  
23  
24 10 context effects will provide knowledge on how the physical environment may be exploited to  
25  
26 11 enhance the effects of exercise therapy in addition to the effect of the specific exercise. Exercise is  
27  
28 12 an effective and widely used core treatment strategy for chronic diseases, such as musculoskeletal  
29  
30 13 disorders, cardio vascular disease and diabetes. Adding to the effect of exercise through context  
31  
32 14 effects from a contextually enhanced physical environment in exercise facilities may be highly  
33  
34 15 beneficial for patients across a number of diseases.  
35  
36  
37  
38  
39  
40

41 17 Previous research in context effects from physical environments has been conducted in hospital  
42  
43 18 settings<sup>27</sup>. A comprehensive review from 2008 showed that certain elements within a hospital  
44  
45 19 context such as noise and lighting level have impact on number of medical errors as well as  
46  
47 20 increased pain and stress levels for patients and staff<sup>27</sup>. Research in other health care settings has  
48  
49 21 been sparse. During an initial literature review only one study was identified investigating physical  
50  
51 22 therapy and its relation to the physical environment. The literature review comprised groups of  
52  
53 23 search terms for context effects, exercise/physical therapy and terms for physical environments.  
54  
55 24 Articles were search for in Medline, Scopus and single specific journals such as Health  
56  
57  
58  
59  
60

1 Environment Research and Design journal. When reviewed, this single study used observation,  
2 surveys and interviews to learn more about the design of a hospital roof-top garden rather than  
3 investigating if the physical environment had an additional effect on the physical therapy<sup>71</sup>. Further,  
4 the therapy of the study was described as activities including gardening, golf putting and events  
5 such as concerts or barbeques, not regular exercise. Consequently, this is to our knowledge the first  
6 study investigating if there is an effect from an enhanced physical environment in addition to  
7 exercise when compared to exercise performed in a standard setting.

8  
9 The three-armed RCT design of the present study has several advantages. It has been widely  
10 discussed whether the placebo effect can be explained by spontaneous remission or regression  
11 towards the mean<sup>15, 72-74</sup>. To rule out either of these as explanatory factors of a possible effect, the  
12 waiting list group is included into the design as an untreated reference group. The waiting list group  
13 illustrates the natural course of disease for the study population during the study period.  
14 Consequently, if a difference is seen between the two exercise rooms, the waiting list group enables  
15 an assessment of whether the difference is caused by spontaneous remission by comparing the  
16 exercise groups to the waiting list. To optimise the number of study participants, a 2:2:1 allocation  
17 with half the number of participants allocated to the waiting list is chosen. The three-armed design  
18 also allows for a test for trend across groups. This form of analysis has been previously applied in a  
19 study investigating context effects originating from patient and practitioner interaction<sup>44</sup>.

20  
21 Context effects are a multifactorial concept and several factors, other than the physical  
22 environment, may contribute to the context effect of a given treatment. Literature reviews on  
23 context effect have additionally suggested factors, such as characteristics of patients/participants,  
24 practitioner/instructors or treatment and nature of disease as potentially contributing to the total

1 context effect and theoretically, components may interact and possibly have synergistic effects<sup>8, 9, 16,</sup>  
2 <sup>24, 75</sup>. Especially the interaction between patient and practitioner has been suggested as a significant  
3 contributor to context effects<sup>44, 76-85</sup>. In a recent study, Kaptchuk et al. found, that patients with  
4 irritable bowel syndrome, who were treated by a warmer and friendlier practitioner, had  
5 significantly better results from sham-acupuncture, than patients treated by a practitioner, who  
6 limited eye-contact and avoided conversation<sup>44</sup>. Similarly, Suarez-Almazor et al. found that knee  
7 osteoarthritis patients treated with sham-acupuncture by a practitioner, who expressed high  
8 expectations to the treatment, had better outcomes than those treated by a practitioner with a neutral  
9 position towards treatment effects<sup>83</sup>. Although the interaction between patient and practitioner is  
10 suggested as the most robust component of context effect, behaviour, communication and  
11 interaction between patient and practitioner is difficult to change and may be hard to reproduce. An  
12 advantage in exploiting the potential context effect from the physical environment is that, the  
13 components of the environment can be thoroughly described and more easily implemented or  
14 changed in existing exercise environments.

15  
16 There are some limitations to the study design that must be acknowledged. The multifactorial  
17 concept of context effects questions whether the physical environment can be isolated and studied  
18 alone. Several actions are taken to isolate the physical environment as the only difference between  
19 groups in this trial. The exercise program is standardised and delivered in a group fashion by the  
20 same instructors and all instructors have supervised in both physical environments. Consequently,  
21 treatment characteristics are similar between the intervention groups. Participants' characteristics,  
22 known and unknown, should be equally distributed between groups as a result of the randomisation  
23 process. Any specific characteristics that may origin from the instructor or from instructor-

1 participant interaction should also be comparable between groups, as instructors supervise in both  
2 rooms.

3 Additionally, the nested qualitative study is aimed to investigate how the physical environment may  
4 affect behaviour of the participants or instructors or the interaction between them. The study will  
5 elucidate these issues and help explain the process of how a standard and enhanced physical  
6 environment affects participants and instructors.

7  
8  
9 This study is designed to investigate the significance of the physical environment for the effects of  
10 exercise therapy and rehabilitation. The design of the study is novel and the results will provide  
11 knowledge on the significance of creating an optimal context for exercise therapy. Further studies  
12 investigating context effects of treatment are warranted to further enhance treatment effects.

13

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 List of abbreviations used

2 CONEX: CONtext effect in EXercise.

3 RCT: Randomised Controlled Trial

4 OA: OsteoArthritis

5 GPE: participant's Global Perceived Effects.

6 EX+ROOM: EXercise in a context enhanced physical environment

7 EX: EXercise in a standard physical environment.

8 WL: waiting list

9 T20: Time for 20dB decay

10 C50: Clarity index, for initial 50 ms.

11 STI: Speech Interpretability Index

12 NEMEX: NEuroMuscular EXercise.

13 KOOS: the Knee Osteoarthritis and injury Outcome Score

14 HOOS: the Hip disability and Osteoarthritis Outcome Score

15 SF-36: Short-Form (36 item) Health Survey

16 ASES: Arthritis Self-Efficacy Scale

17 MVC: Maximal Voluntary Contraction.

18 ANOVA: ANalysis Of VARIation

19

## 20 Acknowledgements

21 Peter Møller Juhl, MSc EE, PhD, Associate Professor for assisting in measuring acoustic properties,

22 and Anne Marie Rosager for invaluable help during the randomisation process.

23

## 24 Funding

1 The study is supported by The Swedish Research Council (2006-4129) and the Faculty of Health at  
2 University of Southern Denmark for funding LFS' salary, and the Danish Rheumatism Association  
3 for supporting the study with a grant (May, 2013). The funding sources had no role in the design of  
4 this study and will not have any role during its execution, analyses, interpretation of the data, or  
5 decision to submit results.

### 6 7 **Competing interests**

8 *The listed author(s) have no competing interests to declare.*

### 9 10 **Author's contributions**

11 LFS, JBT, RU, PD and ER were all involved in the design of the study. All authors contributed to  
12 drafting the manuscript or revising it. All authors read, commented and approved the manuscripts  
13 for publication. LFS is the trial manager and responsible for the coordinating and conducting the  
14 study. LFS, JBT and ER comprise the steering committee for the study. LFS recruits, screens and  
15 conducts all baseline and follow-up testing. LFS monitors the data collection process during the  
16 trial, ensuring high completion rates for email based-surveys, objectively obtained outcomes and  
17 responses to reports of adverse events. Data analysis will be performed by a third party not related  
18 to the study.

### 19 20 **Author affiliation**

21 LFS: MSc, PhD student, Research Unit for Musculoskeletal Function and Physiotherapy at the  
22 Department of Sports Science and Clinical Biomechanics, University of Southern Denmark,  
23 Odense, Denmark.



1  
2  
3  
4 1 JBT: MSc, PhD, Associate Professor; Research Unit for Musculoskeletal Function and  
5  
6 2 Physiotherapy at the Department of Sports Science and Clinical Biomechanics, University of  
7  
8 3 Southern Denmark, Odense, Denmark.

9  
10 4 RU; PhD, Professor, Chalmers University of Technology, Gothenburg, Sweden

11 5 PD; MD, Professor, University of Exeter Medical School, Exeter, UK

12  
13 6 ER: PT, PhD, Professor, Research Unit for Musculoskeletal Function and Physiotherapy at the  
14  
15 7 Department of Sports Science and Clinical Biomechanics, University of Southern Denmark,  
16  
17 8 Odense, Denmark.

18  
19  
20  
21  
22 9

## 23 24 10 **Figure legend**

25  
26 11 Figure 1: Flow chart, overview of the recruitment flow in the CONEX trial.  
27  
28 12

## 29 30 13 **References**

- 31  
32 14
- 33 15 1. Ulrich R. View through a window may influence recovery from surgery. *Science* 1984;**224**(4647):420-21.
  - 34 16 2. Ulrich R, Simons RF, Losito BD, et al. Stress recovery during exposure to natural and urban  
35 17 environments. *Journal of environmental psychology* 1991;**11**:201-30.
  - 36 18 3. Parish JT, Berry LL, Lam SY. The effect of the servicescape on service workers. *J Serv Res-US*  
37 19 2008;**10**(3):220-38.
  - 38 20 4. Malenbaum S, Keefe FJ, Williams AC, et al. Pain in its environmental context: implications for designing  
39 21 environments to enhance pain control. *Pain* 2008;**134**(3):241-4.
  - 40 22 5. Kweon BS, Ulrich RS, Walker VD, et al. Anger and stress - The role of landscape posters in an office  
41 23 setting. *Environment and Behavior* 2008;**40**(3):355-81.
  - 42 24 6. Fransen M, McConnell S, Bell M. Therapeutic exercise for people with osteoarthritis of the hip or knee. A  
43 25 systematic review. *The Journal of Rheumatology* 2002;**29**(8):1738-46.
- 44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1 7. Fransen M, McConnell S. Land-based exercise for osteoarthritis of the knee: a metaanalysis of  
2 randomized controlled trials. *J Rheumatol* 2009;**36**(6):1109-17.
- 3 8. Di Blasi Z, Harkness E, Ernst E, et al. Influence of context effects on health outcomes: a systematic  
4 review. *The Lancet* 2001;**357**(9258):757-62.
- 5 9. Miller FG, Kaptchuk TJ. The power of context: reconceptualizing the placebo effect. *J R Soc Med*  
6 2008;**101**(5):222-5.
- 7 10. Koshi EB, Short CA. Placebo theory and its implications for research and clinical practice: A review of  
8 the recent literature. *Pain practice : the official journal of World Institute of Pain* 2007;**7**(1):4-20.
- 9 11. Kaptchuk TJ. The placebo effect in alternative medicine: can the performance of a healing ritual have  
10 clinical significance? *Ann Intern Med* 2002;**136**(11):817-25.
- 11 12. Beecher HK. The Powerful Placebo. *Jama-J Am Med Assoc* 1955;**159**(17):1602-06.
- 12 13. Miller FG, Rosenstien DL. The nature and power of the placebo effect. *J Clin Epidemiol* 2006;**59**(4):331-  
13 5.
- 14 14. Hrobjartsson A. The uncontrollable placebo effect. *Eur J Clin Pharmacol* 1996;**50**(5):345-8.
- 15 15. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo  
16 with no treatment. *The New England journal of medicine* 2001;**344**(21):1594-602.
- 17 16. Barrett B, Muller D, Rakel D, et al. Placebo, meaning, and health. *Perspect Biol Med* 2006;**49**(2):178-98.
- 18 17. Breidert M, Hofbauer K. Placebo: Misunderstandings and prejudices. *Deutsches Arzteblatt international*  
19 2009;**106**(46):751-55.
- 20 18. Margo CE. The placebo effect. *Surv Ophthalmol* 1999;**44**(1):31-44.
- 21 19. Grunbaum A. The Placebo Concept. *Behav Res Ther* 1981;**19**(2):157-67.
- 22 20. Doherty M, Dieppe P. The "placebo" response in osteoarthritis and its implications for clinical practice.  
23 Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2009;**17**(10):1255-62.
- 24 21. Paterson C, Dieppe P. Characteristic and incidental (placebo) effects in complex interventions such as  
25 acupuncture. *BMJ* 2005;**330**(7501):1202-5.
- 26 22. Dellmann T, Lushington K. How can complementary medicine practitioners enhance non-specific  
27 effects? *journal of the Australian Traditional-Medicine Society* 2008;**14**(1):13-17.

- 1  
2  
3  
4 1 23. Dieppe P, Doherty M. Contextualizing osteoarthritis care and the reasons for the gap between evidence  
5  
6 2 and practice. *Clin Geriatr Med* 2010;**26**(3):419-31.  
7  
8 3 24. Moerman DE, Jonas WB. Deconstructing the placebo effect and finding the meaning response. *Ann*  
9  
10 4 *Intern Med* 2002;**136**(6):471-6.  
11  
12 5 25. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 Statement: updated guidelines for reporting  
13  
14 6 parallel group randomised trials. *BMC Med* 2010;**8**.  
15  
16 7 26. Kuttruff H. *Room acoustics*. London: Spon Press, 2000.  
17  
18 8 27. Ulrich RS, Zimring C, Zhu XM, et al. A Review of the Research Literature on Evidence-Based  
19  
20 9 *Healthcare Design*. *Herd-Health Env Res* 2008;**1**(3):61-125.  
21  
22 10 28. Shepley MM, Gerbi RP, Watson AE, et al. The Impact of Daylight and Views on ICU Patients and Staff.  
23  
24 11 *Health Environments Research & Design Journal (HERD)* 2012;**5**(2):46-60.  
25  
26 12 29. Walch JM, Rabin BS, Day R, et al. The effect of sunlight on postoperative analgesic medication use: A  
27  
28 13 prospective study of patients undergoing spinal surgery. *Psychosom Med* 2005;**67**(1):156-63.  
29  
30 14 30. Ulrich RS. Human Responses to Vegetation and Landscapes. *Landscape Urban Plann* 1986;**13**(1):29-44.  
31  
32 15 31. Ulrich RS. Natural Versus Urban Scenes - Some Psychophysiological Effects. *Environment and*  
33  
34 16 *Behavior* 1981;**13**(5):523-56.  
35  
36 17 32. Tse MMY, NG JKF, Chung JWY, et al. The effect of visual stimuli on pain threshold and tolerance. *J*  
37  
38 18 *Clin Nurs* 2002;**11**:462-69.  
39  
40 19 33. Diette GB, Lechtzin N, Haponik E, et al. Distraction therapy with nature sights and sounds reduces pain  
41  
42 20 during flexible bronchoscopy: a complementary approach to routine analgesia. *Chest*  
43  
44 21 2003;**123**(3):941-8.  
45  
46 22 34. Ageberg E, Link A, Roos EM. Feasibility of neuromuscular training in patients with severe hip or knee  
47  
48 23 OA: the individualized goal-based NEMEX-TJR training program. *BMC Musculoskelet Disord*  
49  
50 24 2010;**11**:126.  
51  
52 25 35. Zätterström R, Friden T, Linstrand A, et al. Early rehabilitation of acute anterior cruciate ligament injury  
53  
54 26 - a randomized clinical trial. *Scand J Med Sci Sports* 1998(8):154-59.  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 1 36. Ageberg E, Zätterström R, Moritz U, et al. Influence of Supervised and Nonsupervised Training on  
5  
6 2 Postural Control After an Acute anterior Cruciate Ligament Rupture: A Three-year Longitudinal  
7  
8 3 Prospective Study. *J Orthop Sports Phys Ther* 2001;**31**(11):632-44.  
9  
10 4 37. Ageberg E. Consequences of a ligament injury on neuromuscular function and relevance to rehabilitation  
11  
12 5 - using the anterior cruciate ligament injured knee as model. *J Electromyogr Kinesiol* 2002;**12**:205 -  
13  
14 6 12.  
15  
16 7 38. Zätterström R, Friden T, Lindstrand A, et al. Muscle training in chronic anterior cruciate ligament  
17  
18 8 insufficiency--a comparative study. *Scand J Rehabil Med* 1992;**24**(2):91-7.  
19  
20 9 39. Roos EM, Dahlberg L. Positive effects of moderate exercise on glycosaminoglycan content in knee  
21  
22 10 cartilage: a four-month, randomized, controlled trial in patients at risk of osteoarthritis. *Arthritis*  
23  
24 11 *Rheum* 2005;**52**(11):3507-14.  
25  
26 12 40. Ericsson YB, Dahlberg LE, Roos EM. Effects of functional exercise training on performance and muscle  
27  
28 13 strength after meniscectomy: a randomized trial. *Scand J Med Sci Sports* 2009;**19**(2):156-65.  
29  
30 14 41. Villadsen A, Overgaard S, Holsgaard-Larsen A, et al. Postoperative effects of neuromuscular exercise  
31  
32 15 prior to hip or knee arthroplasty: a randomised controlled trial. *Ann Rheum Dis* 2013.  
33  
34 16 42. Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses  
35  
36 17 and considerations for design. *J Man Manip Ther* 2009;**17**(3):163-70.  
37  
38 18 43. Guyatt GH, Norman GR, Juniper EF, et al. A critical look at transition ratings. *J Clin Epidemiol*  
39  
40 19 2002;**55**(9):900-8.  
41  
42 20 44. Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised controlled trial in  
43  
44 21 patients with irritable bowel syndrome. *BMJ* 2008;**336**(7651):999-1003.  
45  
46 22 45. Roos E, Lohmander S. The knee injury and osteoarthritis outcome score (KOOS) - from joint injury to  
47  
48 23 osteoarthritis. *Health and Quality of Life Outcomes* 2003.  
49  
50 24 46. Klassbo M, Larsson E, Mannevik E. Hip disability and osteoarthritis outcome score. An extension of the  
51  
52 25 Western Ontario and McMaster Universities Osteoarthritis Index. *Scand J Rheumatol* 2003;**32**(1):46-  
53  
54 26 51.  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 1 47. Roos E, Roos H, Lohmander S, et al. Knee injury and osteoarthritis outcome score (KOOS) -  
5  
6 2 development of a self-administered outcome measure. *J Orthop Sports Phys Ther* 1998;**78**(2):88-96.  
7  
8 3 48. Roos EM, Toksvig-Larsen S. Knee injury and Osteoarthritis Outcome Score (KOOS) - validation and  
9  
10 4 comparison to the WOMAC in total knee replacement. *Health Qual Life Outcomes* 2003;**1**:17.  
11  
12 5 49. Roos EM, Roos HP, Ekdahl C, et al. Knee injury and Osteoarthritis Outcome Score (KOOS)--validation  
13  
14 6 of a Swedish version. *Scand J Med Sci Sports* 1998;**8**(6):439-48.  
15  
16 7 50. Nilsson AK, Lohmander LS, Klassbo M, et al. Hip disability and osteoarthritis outcome score  
17  
18 8 (HOOS)--validity and responsiveness in total hip replacement. *BMC Musculoskelet Disord*  
19  
20 9 2003;**4**:10.  
21  
22 10 51. Mchorney CA, Ware JE, Raczek AE. The Mos 36-Item Short-Form Health Survey (Sf-36) .2.  
23  
24 11 Psychometric and Clinical-Tests of Validity in Measuring Physical and Mental-Health Constructs.  
25  
26 12 *Med Care* 1993;**31**(3):247-63.  
27  
28 13 52. Mchorney CA, Ware JE, Lu JFR, et al. The Mos 36-Item Short-Form Health Survey (Sf-36) .3. Tests of  
29  
30 14 Data Quality, Scaling Assumptions, and Reliability across Diverse Patient Groups. *Med Care*  
31  
32 15 1994;**32**(1):40-66.  
33  
34 16 53. Ware JE, Sherbourne CD. The Mos 36-Item Short-Form Health Survey (Sf-36) .1. Conceptual-  
35  
36 17 Framework and Item Selection. *Med Care* 1992;**30**(6):473-83.  
37  
38 18 54. Bandura A. Self-Efficacy - toward a Unifying Theory of Behavioral Change. *Psychol Rev*  
39  
40 19 1977;**84**(2):191-215.  
41  
42 20 55. Lorig K, Chastain RL, Ung E, et al. Development and evaluation of a scale to measure perceived self-  
43  
44 21 efficacy in people with arthritis. *Arthritis Rheum* 1989;**32**(1):37-44.  
45  
46 22 56. Skou ST, Odgaard A, Rasmussen JO, et al. Group education and exercise is feasible in knee and hip  
47  
48 23 osteoarthritis. *Dan Med J* 2012;**59**(12):A4554.  
49  
50 24 57. Brady TJ. Measures of self-efficacy: Arthritis Self-Efficacy Scale (ASES), Arthritis Self-Efficacy Scale-  
51  
52 25 8 Item (ASES-8), Children's Arthritis Self-Efficacy Scale (CASE), Chronic Disease Self-Efficacy  
53  
54 26 Scale (CDSSES), Parent's Arthritis Self-Efficacy Scale (PASE), and Rheumatoid Arthritis Self-  
55  
56 27 Efficacy Scale (RASE). *Arthritis Care Res (Hoboken)* 2011;**63 Suppl 11**:S473-85.  
57  
58  
59  
60


- 1  
2  
3  
4 1 58. Tubach F, Ravaud P, Baron G, et al. Evaluation of clinically relevant states in patient reported outcomes  
5  
6 2 in knee and hip osteoarthritis: the patient acceptable symptom state. *Ann Rheum Dis* 2005;**64**(1):34-  
7  
8 3 7.  
9  
10 4 59. Lesage FX, Berjot S. Validity of occupational stress assessment using a visual analogue scale. *Occup*  
11  
12 5 *Med (Lond)* 2011;**61**(6):434-6.  
13  
14 6 60. Astrand PO, Ryhming I. A nomogram for calculation of aerobic capacity (physical fitness) from pulse  
15  
16 7 rate during sub-maximal work. *J Appl Physiol* 1954;**7**(2):218-21.  
17  
18 8 61. Thorborg K, Bandholm T, Holmich P. Hip- and knee-strength assessments using a hand-held  
19  
20 9 dynamometer with external belt-fixation are inter-tester reliable. *Knee Surg Sports Traumatol*  
21  
22 10 *Arthrosc* 2013;**21**(3):550-5.  
23  
24 11 62. Ageberg E, Bennell KL, Hunt MA, et al. Validity and inter-rater reliability of medio-lateral knee motion  
25  
26 12 observed during a single-limb mini squat. *BMC Musculoskelet Disord* 2010;**11**.  
27  
28 13 63. Bremander AB, Dahl LL, Roos EM. Validity and reliability of functional performance tests in  
29  
30 14 meniscectomized patients with or without knee osteoarthritis. *Scand J Med Sci Sports*  
31  
32 15 2007;**17**(2):120-7.  
33  
34 16 64. Thorlund JB, Aagaard P, Roos EM. Thigh muscle strength, functional capacity, and self-reported  
35  
36 17 function in patients at high risk of knee osteoarthritis compared with controls. *Arthritis Care Res*  
37  
38 18 (Hoboken) 2010;**62**(9):1244-51.  
39  
40 19 65. Dobson F, Hinman RS, Hall M, et al. Measurement properties of performance-based measures to assess  
41  
42 20 physical function in hip and knee osteoarthritis: a systematic review. *Osteoarthritis Cartilage*  
43  
44 21 2012;**20**(12):1548-62.  
45  
46 22 66. Dobson F, Hinman RS, Roos EM, et al. OARSI recommended performance-based tests to assess physical  
47  
48 23 function in people diagnosed with hip or knee osteoarthritis. *Osteoarthritis Cartilage* 2013.  
49  
50 24 67. Wright AA, Cook CE, Baxter GD, et al. A comparison of 3 methodological approaches to defining major  
51  
52 25 clinically important improvement of 4 performance measures in patients with hip osteoarthritis. *J*  
53  
54 26 *Orthop Sports Phys Ther* 2011;**41**(5):319-27.  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 1 68. Gill S, McBurney H. Reliability of performance-based measures in people awaiting joint replacement  
5  
6 2 surgery of the hip or knee. *Physiother Res Int* 2008;**13**(3):141-52.  
7  
8 3 69. Tsai CY, Wang MC, Liao WT, et al. Hospital outpatient perceptions of the physical environment of  
9  
10 4 waiting areas: the role of patient characteristics on atmospherics in one academic medical center.  
11  
12 5 *BMC Health Serv Res* 2007;**7**.  
13  
14 6 70. Jarvinen TLN, Sihvonen R, Bhandari M, et al. Blinded interpretation of study results can feasibly and  
15  
16 7 effectively diminish interpretation bias. *J Clin Epidemiol* 2014;**67**(7):769-72.  
17  
18 8 71. Davis BE. Rooftop Hospital Gardens for Physical Therapy: A Post-Occupancy Evaluation. *Health*  
19  
20 9 *Environments Research & Design Journal (HERD)* 2011;**4**(3):14-43.  
21  
22 10 72. Hrobjartsson A, Gotzsche PC. Placebo treatment versus no treatment. *Cochrane database of systematic*  
23  
24 11 *reviews* 2003(1):CD003974.  
25  
26 12 73. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? Update of a systematic review with 52 new  
27  
28 13 randomized trials comparing placebo with no treatment. *J Intern Med* 2004;**256**(2):91-100.  
29  
30 14 74. Thompson WG. Placebos: a review of the placebo response. *The American journal of gastroenterology*  
31  
32 15 2000;**95**(7):1637-43.  
33  
34 16 75. Di Blasi Z, Kleijnen J. Context effects. Powerful therapies or methodological bias? *Eval Health Prof*  
35  
36 17 2003;**26**(2):166-79.  
37  
38 18 76. Lang EV, Hatsiopoulou O, Koch T, et al. Can words hurt? Patient-provider interactions during invasive  
39  
40 19 procedures. *Pain* 2005;**114**(1-2):303-09.  
41  
42 20 77. Benedetti F, Amanzio M. The placebo response: how words and rituals change the patient's brain. *Patient*  
43  
44 21 *Educ Couns* 2011;**84**(3):413-9.  
45  
46 22 78. Bensing JM, Verheul W. The silent healer: the role of communication in placebo effects. *Patient Educ*  
47  
48 23 *Couns* 2010;**80**(3):293-9.  
49  
50 24 79. Essers G, Kramer A, Andriess B, et al. Context factors in general practitioner - patient encounters and  
51  
52 25 their impact on assessing communication skills - an exploratory study. *BMC Fam Pract* 2013;**14**.  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3  
4 1 80. Griffin SJ, Kinmonth AL, Veltmn MWM, et al. Effect on health-related outcomes of interventions to  
5  
6 2 alter the interaction between patients and practitioners: A systematic review of trials. *Ann Fam Med*  
7  
8 3 2004;**2**(6):595-608.  
9  
10 4 81. Lonsdale C, Hall AM, Williams GC, et al. Communication style and exercise compliance in  
11  
12 5 physiotherapy (CONNECT): a cluster randomized controlled trial to test a theory-based intervention  
13  
14 6 to increase chronic low back pain patients' adherence to physiotherapists' recommendations: study  
15  
16 7 rationale, design, and methods. *BMC Musculoskelet Disord* 2012;**13**:104.  
17  
18 8 82. Neumann M, Edelhauser F, Kreps GL, et al. Can patient-provider interaction increase the effectiveness  
19  
20 9 of medical treatment or even substitute it?--an exploration on why and how to study the specific  
21  
22 10 effect of the provider. *Patient Educ Couns* 2010;**80**(3):307-14.  
23  
24 11 83. Suarez-Almazor ME, Looney C, Liu Y, et al. A randomized controlled trial of acupuncture for  
25  
26 12 osteoarthritis of the knee: effects of patient-provider communication. *Arthritis Care Res*  
27  
28 13 2010;**62**(9):1229-36.  
29  
30 14 84. Teutsch C. Patient-doctor communication. *Med Clin North Am* 2003;**87**(5):1115-45.  
31  
32 15 85. Thomas K. General practice consultations\_is there any point in being positive? *Br Med J*  
33  
34 16 1987;**294**(may):1200-02.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





183x193mm (300 x 300 DPI)





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	N/A
Funding	4	Sources and types of financial, material, and other support	27
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	28
	5b	Name and contact information for the trial sponsor	N/A
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	28
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	22, <u>28</u>

1				
2				
3	<b>Introduction</b>			
4				
5	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant	5-7
6	rationale		studies (published and unpublished) examining benefits and harms for each intervention	
7				
8		6b	Explanation for choice of comparators	8,12,23
9				
10	Objectives	7	Specific objectives or hypotheses	6,7
11				
12	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),	7
13			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	
14				
15				
16	<b>Methods: Participants, interventions, and outcomes</b>			
17				
18	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will	N/A
19			be collected. Reference to where list of study sites can be obtained	
20				
21	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	7-8
22			individuals who will perform the interventions (eg, surgeons, psychotherapists)	
23				
24	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be	8-12
25			administered	
26				
27		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose	N/A
28			change in response to harms, participant request, or improving/worsening disease)	
29				
30		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence	15-18
31			(eg, drug tablet return, laboratory tests)	
32				
33		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N/A
34				
35	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	12-18
36			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,	
37			median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen	
38			efficacy and harm outcomes is strongly recommended	
39				
40	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for	Fig.1.
41			participants. A schematic diagram is highly recommended (see Figure)	
42				
43				
44				
45				
46				
47				
48				
49				

1				
2				
3	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	20
4				
5				
6	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	8
7				
8	<b>Methods: Assignment of interventions (for controlled trials)</b>			
9				
10	Allocation:			
11				
12	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	19
13				
14				
15				
16				
17				
18	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	19
19				
20				
21				
22	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	19
23				
24				
25	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	19-20
26				
27				
28		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	19-20
29				
30				
31				
32	<b>Methods: Data collection, management, and analysis</b>			
33				
34	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	12-20
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	15
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				

1				
2				
3	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	N/A
4				
5				
6				
7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	20-22
8				
9				
10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	N/A
11				
12		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	22
13				
14				
15				
16	<b>Methods: Monitoring</b>			
17				
18	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	<u>16</u> ,22,28
19				
20				
21				
22				
23		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
24				
25				
26	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	18-19
27				
28				
29	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N/A
30				
31				
32				
33	<b>Ethics and dissemination</b>			
34				
35	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	7,25
36				
37				
38	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	N/A
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				

1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	<del>N/A</del> <u>8</u>
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
7				
8				
9	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	N/A
10				
11				
12	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	28
13				
14				
15	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	N/A
16				
17				
18	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
19				
20				
21	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	<del>N/A</del> <u>22</u>
22				
23				
24				
25				
26		31b	Authorship eligibility guidelines and any intended use of professional writers	N/A
27				
28		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N/A
29				
30	<b>Appendices</b>			
31				
32	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	N/A
33				
34				
35	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A
36				
37				

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.